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Chapter 1 - Introduction 
1.1 Cell and gene therapy 
Immunotherapy, cell-based therapy, and gene therapy are exciting areas of current research, each 
individually holding great future promise for the treatment of human disease. One particularly promising 
area of overlap for these three related research disciplines is in the genetic modification of T 
lymphocytes for use in adoptive cell transfer. 
 Immunotherapy has no strict definition but is generally understood to mean the use of 
components of the immune system in the treatment of human disease. There are many forms of 
immunotherapy already available, for example in the use of vaccination for the prevention or treatment 
of infectious diseases. In the field of cancer research one somewhat arbitrary classification is that of 
active immunotherapy, where a recipient immune system is induced to respond against the relevant 
cancer (usually by means of a vaccine), versus passive immunotherapy, where immune system 
components generated ex-vivo are administered to the recipient for the desired response (Mellman et 
al. 2011). Monoclonal antibody (mAb) therapies and adoptive transfer of T-cells are examples of 
passive immunotherapy. The common theme is the use of the immune system to reject cancer. 
 Cell-based therapy is a very broad term, incorporating adoptive T-cell therapies as a subset, 
but also can be more widely understood to include the established use of haematopoietic stem cell 
transplant (HSCT) for treatment of haematologic malignancies and related problems, right through to 
the enormous potential of embryonic stem cells or induced pluripotent stem cells for human therapies. 
Gene therapy has been traditionally understood to mean the correction of a genetic abnormality in cells, 
but now may more broadly include the introduction of novel transgenes into cells to enhance certain 
functions (for example T-cell specificity) or change cell behaviour (such as induced pluripotent stem 
cells).  
This review will focus on T-cell therapies, particularly their use following allogeneic HSCT, and 
in genetic engineering of T-cells to express chimeric immunoreceptors against cancer antigens. To 
place the use of these technologies in context we will briefly review the lymphoid malignancies and the 
use and difficulties of haematopoietic stem cell transplantation.  
1.1.1 Components of the immune system 
A full explanation of immunotherapy in cancer treatment presupposes knowledge of the human immune 
system. In brief the innate immune system is comprised of those components which defend the host 
from infections in a generic non-specific way. The cutaneous and mucosal integument is the first line of 
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defence, and is loosely defined as a component of the innate immune system. However the term has 
come to encompass the inflammatory, histaminergic, and complement cascades more so than 
anatomic barriers. The cellular components of innate immunity include neutrophils, antigen presenting 
cells (APC), Natural Killer lymphocytes and others which respond immediately to well defined, fixed, 
antigenic patterns. The innate cellular response does not change with antigen exposure and is not 
involved directly with immune “memory” for specific pathogens. In contrast the adaptive immune system 
(also known as the specific immune system) refers to those immune components involved with specific 
pathogen recognition. The adaptive immune response is altered and refined by the specific organisms 
or antigens encountered, with the development of long lasting immune memory for pathogens, enabling 
more rapid response to threats on re-exposure. The subcomponents of the adaptive immune system 
include humoral immunity (relating to specific antibody recognition) and cellular immunity (T-cell related 
immunity). The majority of this review and presented research concerns components of the adaptive, 
cellular immune system.  
  
1.2  B-cell Lymphoid Malignancies 
As this thesis pertains to the redirection of T-cell specificity to target the CD19 antigen, which is 
expressed on B-cells, a brief review of B-cell malignancy and treatments will follow. Haematological 
malignancies derived from lymphocytes or their precursors are common and often fatal diseases which 
affect children and adults alike. Malignant lymphoid disorders are currently classified by the World 
Health Organisation (WHO) as either precursor lymphoid neoplasms such as precursor B Acute 
Lymphoblastic Leukaemia (ALL), or mature B-, T-, or NK-cell neoplasms, of which there are a large 
number of distinct entities (Swerdlow et al. 2008).   
Acute Lymphoblastic Leukaemia is the commonest cancer of childhood in Australia from age 1 
to 15 years for both sexes (AIHW 2008), and precursor B-cell ALL is the commonest subtype, 
accounting for ~80% of cases. With combination chemotherapy and radiotherapy the overall 5-year 
survival rate for paediatric leukaemia has improved greatly, to above 90% in the mid-2000s (Hunger et 
al. 2012). In contrast ALL is a relatively rare cancer in adults, although incidence increases with 
advancing age, and it carries a poor prognosis even with modern chemotherapy regimens. Standard 
treatment for ALL consists of polychemotherapy regimens scheduled for up to several years, with 
radiotherapy used for central nervous system (CNS) disease, as well as allogeneic HSCT in select 
patients with poor prognosis. 
The commonest mature lymphoid neoplasms are the B-cell non-Hodgkin’s lymphomas (NHL) 
and chronic lymphoproliferative disorders such as B-cell Chronic Lymphocytic Leukaemia (CLL). 
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Overall this group is the commonest of the ‘lymphohaematopoietic’ cancers, accounting for ~5000 
overall new cases in Australia in 2005. This rate is projected to increase over the coming decades 
(AIHW 2008). The reasons for this increasing incidence are unclear. Standard treatment of mature B-
cell neoplasms varies depends on the histological subtype as well as patient factors such as age and 
comorbidities, but in general involves combination chemotherapy regimens, coupled with radiotherapy 
in some cases. Recently the addition of antibody based immunotherapy targeting the mature B-cell 
antigen CD20 with rituximab (trade name ‘Mabthera’)  has become standard of care in most cases of B-
cell NHL and CLL (Hagemeister 2010). 
1.2.1 Rationale for research into novel therapies  
New treatments are needed for lymphoid malignancies. Tragically 10% of children still die from ALL in 
the modern era (Hunger et al. 2012), with much higher mortality in sub-groups such as infant ALL, and 
the survivors face years of chemotherapy and hospital visits, and long-term sequelae such as 
neurocognitive effects, secondary cancers and fertility issues (Robison and Bhatia 2003). Survival for 
adults with ALL and aggressive lymphoma is worse than in children across the board. There is currently 
a worldwide research effort into improving treatment schedules in terms of efficacy and tolerability. 
However increasing the dose intensity or number of cytotoxic chemotherapy agents in combination 
schedules is likely to have diminishing returns from now on, with some schedules already at the 
maximum dose tolerability even for young patients.  
By contrast research into targeted therapy for malignancies offers the hope of adding to 
treatment efficacy without increasing toxicity, and the B-cell lymphoid malignancies hold particular 
promise as they often have well defined potential targets. In terms of molecular targets, precursor-B 
ALL expressing the Philadelphia chromosome has traditionally been regarded as one of the worst 
prognostic groups within ALL, but is sensitive to treatment with the tyrosine kinase inhibitor (TKI) 
imatinib and its derivatives. TKI treatment is likely to improve the survival in this subgroup dramatically 
(Bassan et al. 2010). There are other well-defined novel fusion genes underlying oncogenesis of other 
B-cell malignancies (such as c-myc translocations in Burkitt’s lymphoma) which are potential targets for 
small molecule specific inhibitors, as are many other oncogenic pathways. However no molecularly 
targeted treatments have yet entered routine clinical practice for lymphoid malignancies other than the 
TKIs. 
1.2.2 Immunotherapeutic approaches for B-cell lymphoid malignancies 
The most promising novel therapies for B-cell malignancies come from immunotherapy, which is the 
main focus of this thesis. B-cells express a selection of specific antigens on their cell surface at various 
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stages of maturation, many of which are suitable targets for specific therapy. Every mature B-cell 
neoplasm expresses a clonal B-cell receptor (BCR) which is a potential immunotherapy target, and 
research into idiotype vaccination as a form of active immunotherapy for follicular lymphoma is ongoing, 
though hampered by recent negative trial results (Bendandi 2009). In addition the expense of 
personalising vaccination to such a degree is prohibitive. There are other active immunotherapy 
approaches undergoing early phase trial assessment, including direct intra-tumoral vaccination and 
dendritic cells vaccines pulsed with tumour idiotype, which hold promise. 
 
 
 
Figure 1-1 Normal B-cell Development. 
Murine and human B-cell development occurs over a spectrum from marrow progenitors to plasma 
cells. B-1 cells are non-memory B cells involved in the humoral response with natural antibody 
production. CLP: common lymphoid progenitor; SHM: somatic hyper mutation; CSR: class-switch 
recombination. From LeBien and Tedder (LeBien and Tedder 2008). 
 
 Apart from the tumour specific idiotype, both normal and neoplastic B-cells also express a 
variety of specific surface receptors which are potential targets for immunotherapy. In general the 
expression of B cell receptors on the cell membrane of specific tumours reflects the cell of origin of that 
tumour, which in turn reflects the relative development maturity of that cell on the spectrum from bone 
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marrow precursor to plasma cell, illustrated in Figure 1-1 and Figure 1-2. For example, the classic 
germinal centre derived B-cell malignancy will express CD10 as well as other B cell markers. Important 
B-cell surface antigens for immunotherapy targets include CD19, CD20, and CD22 amongst others. 
Thus far the various functions of these B-cell surface receptors are not fully elucidated. CD20 appears 
to be a membrane embedded Ca++ channel, though it’s exact function is obscure (LeBien and Tedder 
2008).  
 
 
Figure 1-2 B-cell antigen expression during development.  
(Edwards and Cambridge 2006) 
 
 CD20 is expressed on mature B cells only, and rarely on B-ALL where it appears to portend a 
poorer prognosis. The ‘first in class’ B-cell targeted monoclonal antibody (mAb) to reach standard 
clinical practice was rituximab which specifically targets CD20, and there are several next generation 
anti-CD20 directed monoclonals under clinical evaluation at present. Whether the efficacy of anti-CD20 
targeted antibodies reflects antibody specific effects or issues related to CD20 itself as a target is not 
yet clarified. Targeting other B-cell antigens with monoclonal antibodies analogous to rituximab and 
derivatives has not yet borne fruit in terms of therapeutic effect.  
1.2.3 CD19 as a therapeutic target 
CD19 is expressed selectively in all B-lineage cells (‘pan-B-cell expression’), and consequently is 
expressed by all B-cell malignancies, though only weakly on plasma cell myeloma. CD19 is not 
expressed on haematopoietic stem cells, and has minimal off target expression apart from minor 
expression on follicular dendritic cells. It is a member of the immunoglobulin superfamily which appears 
to regulate BCR signal transduction by interaction with Src-family kinases.   
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The restriction in expression of CD19 to B-cells, and consequential expression in a wide range 
of B-cell malignancies, makes it a highly promising therapeutic target for immunotherapy with 
theoretical complementary activity to existing anti-CD20 therapy. There are 4 broad immunotherapeutic 
approaches targeting CD19 under evaluation worldwide:  
(i) Monoclonal antibody therapies. To date this approach has been a non-starter due to lack of 
clinical effect due to low antibody dependent cellular cytotoxicity (ADCC) or complement-dependent 
cytotoxicity (CDC) in CD19 directed antibodies. However recent developments in ‘glycoengineering’ the 
Fc portion of anti-CD19 monoclonal antibodies to improve the natural killer cell (NK-cell) mediated 
ADCC may improve matters. Ward et al have published in vitro results using MEDI-551, derived from a 
murine IgG1 anti-CD19 mAb generated within a fucosyltransferase deficient producer cell line (Ward et 
al. 2011). This ‘afucosylation’ increases the ADCC markedly in comparison to the parental mAb. The 
authors showed that MEDI-551 could be combined synergistically with rituximab against cell lines, 
primary CLL or ALL samples, and in murine lymphoma models. Early phase clinical trials using MEDI-
551 are underway in the US. 
(ii) Antibody-drug conjugates, where a toxin is linked to a CD19 specific mAb. This concept has 
been used with promising effect in the setting of CD33+ acute myeloid leukaemia (AML) with 
gemtuzumab ozagamicin, and with particular promise against refractory/relapsed CD30+ lymphoma 
using brentuximab vedotin (Younes et al. 2010). The approach works best where the target surface 
antigen has been shown to internalise after mAb binding. For CD19 the closest to the clinic is 
SAR3419, under development by Sanofi, for which a phase I trial has been reported (Blanc et al. 2011).  
 
 
 
BiTEs (bispecific T-cell engagers) act to 
facilitate an immune synapse between tumour 
cells and cytotoxic T-cells, leading to BiTE-
dependent cellular cytotoxicity. Figure from 
Wikipedia commons (29/5/2012). 
Figure 1-3 BiTE Antibody Mechanism. 
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(iii) Bispecific T-cell Engager antibodies, or ‘BiTE’ antibodies. BiTE antibodies consist of two single 
chain variable fragments (‘scFv’), one targeting CD19, and the other against CD3. scFvs are 
engineered protein fragments consisting of the smallest functional VH and VL domains, which determine 
antigenic specificity, from a functional mAb, joined by a short linker (Figure 1-4). scFv have shown to 
maintain the same antigen specificity and similar affinity to the parent intact monoclonal (Bird et al. 
1988, Weisser and Hall 2009). By targeting one scFv to the antigen of interest, and the other to the T-
cell receptor antigen CD3, the BiTE is able to activate T-cells against cells bearing the target antigen. 
An illustration of BiTE design and activity is shown in Figure 1-3.  
 
  
Figure 1-4 Single chain Variable fragment schematic  
VH: heavy chain variable domain, VL: light chain variable domain, L: linker peptide. (Weisser and Hall 
2009) 
 
 Blinatumomab is the first-in-class BiTE, formerly called MT103/MEDI-538. Early phase human 
trials in CD19+ ALL or lymphoproliferative disease (LPD) have been extremely encouraging, both in the 
refractory/relapsed setting (Handgretinger et al. 2011) and also in converting patients with minimal 
residual disease (MRD+) to molecular remission (MRD-) (Topp et al. 2011). The downside with 
blinatumomab has been neurotoxicity, with seizures and encephalopathy potentially limiting its 
application to the relapse setting. Registration phase III trials have been initiated in Europe and the US. 
(iv) The fourth approach is to redirect T-cell specificity using a chimeric antigen receptor (CAR). 
CARs will be reviewed in a later section. 
1.2.4 Iatrogenic B-cell aplasia 
One of the most important lessons learnt from the human research experience with anti-CD20 directed 
therapies is the relative lack of toxicity seen with profound B-cell depletion for prolonged periods. 
Rituximab therapy is invariably followed by prolonged selective lymphopenia of normal B-cells, 
accompanied often by hypogammaglobulinaemia. However the clinical side-effects of this B-
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lymphopenia have proved to be remarkably mild. The best level of evidence for this comes from large 
randomised controlled trials of prolonged rituximab maintenance following therapy for follicular 
lymphoma, such as the PRIMA trial (Salles et al. 2011). There was an increase in infection of toxicity 
grade 2-4 in the R-maintenance arm (36% vs. 24%, P<0.0001), but only one death was reported as 
probably related to rituximab, being fulminant hepatitis-B virus (HBV). On the basis of this and other 
reports patients with HBV seropositivity are now given prophylactic antivirals when on anti B-cell 
therapy. Rituximab maintenance is now regarded as standard of care in the treatment of follicular 
lymphoma. The profound B-cell depletion seen with anti-CD20 antibody therapy has not proven to be a 
significant burden of toxicity for patients so far. 
 
1.2.5 Haematopoietic stem cell transplantation for B-cell malignancies 
 
The success of HSCT lies in the ability to either replace bone marrow with a healthy source in the case 
of non-malignant indications (such as inherited marrow failure syndromes and acquired aplastic 
anaemia), or to administer chemotherapy doses in excess of the previously identified maximum 
tolerated dose (MTD) for the treatment of malignancies. In the case of allogeneic HSCT (allo-HSCT), 
where the stem cells originate from a tissue type matched donor as opposed to oneself, there is an 
additional benefit of decreased relapse rate compared to chemotherapy alone. This is thought to be 
due to a donor derived immune response to recipient malignant cells- the Graft-versus-
Leukaemia/Lymphoma (GvL) effect. However HSCT does not come without risk to the recipient, with 
problems of chemotherapy toxicity, prolonged immunosuppression, and the risk of Graft-versus-Host 
Disease (GvHD) in the case of allogeneic HSCT, leading to morbidity or transplant-related mortality in 
some cases. 
 Allogeneic HSCT plays an important role in the treatment of various B-cell lymphoproliferative 
disorders, and indeed is the only curative therapy in certain settings. The mechanism of action of 
allogeneic HSCT is twofold: firstly the conditioning therapy prior to transplant provides some degree of 
disease control, but is generally regarded as the minor component of HSCT efficacy; and secondly 
there is a graft-versus-tumour (GVT) effect primarily mediated by allogeneic T-cells. More detail on the 
anatomy of the GVT effect is given in a later section of this review. Conversely allogeneic HSCT is quite 
risky, particularly when given in heavily pre-treated and frail cancer patients. For this reason in the last 
decade there has been considerable development of less toxic ‘reduced-intensity conditioning’ (RIC) 
regimens, which allow older and less fit patients to undergo transplantation.  
 
18 
 
Chapter 1 - Introduction 
 
 The role of allogeneic HSCT in relapsed Philadelphia-chromosome negative B-cell ALL is clear 
cut: there are no cures with chemotherapy alone following relapse of ALL (Oliansky et al. 2012). 
Several studies have shown that the survival of patients in this circumstance is dismal with 
chemotherapy alone, although allograft results are no panacea either, with 4-year survival rates in the 
order of 16% - 23% only (Fielding et al. 2007). In contrast the role of allogeneic HSCT in fist remission 
of ALL is quite controversial, particularly in the area of Philadelphia-chromosome positive ALL which 
now has targeted TKI agents available. Allogeneic transplant in first remission from ALL is 
recommended only in high risk circumstances, which is currently defined by specific cytogenetic 
abnormalities and persistent MRD with standard therapy. The presence of a ‘Graft-versus-Leukaemia’ 
(GvL) effect has been unclear in ALL so far, but studies have shown that the ALL relapse rate after 
allogeneic transplant is lower than after syngeneic transplant (i.e. from an identical twin) (Gale et al. 
1994) indicating an additional benefit to allogeneic donor cells. 
 Indolent B-cell malignancies, such as low-grade lymphomas and B-CLL, are also treated with 
allogeneic transplant in the late, multiply relapsed phase of disease. Transplant related toxicity in these 
cases is high, possibly due to the heavy pre-treatment these patients have, and so RIC transplants are 
the norm. In terms of CLL the vast majority of patients will relapse after initial treatment, but as the 
patient group has a median age over 70, allogeneic transplant is generally reserved the minority who 
are fit and young. There are no randomised trials of allogeneic HSCT over other types of transplant in 
this setting, but there do appear to be cures in even multiply relapsed patients with RIC, with 84% of 
patients in CR initially remaining well without relapse after 5 years with one of the largest RIC trials 
(Sorror et al. 2008). GvL effects in CLL are again not as clear as they are with CML and other myeloid 
disorders, however responses have occurred to donor lymphocyte infusions (DLI) without 
chemotherapy, indicating that in CLL a GvL effect exists (Russell et al. 2005, El-Jurdi et al. 2013). The 
GvL effect is also well established in low-grade lymphoma such as follicular non-Hodgkin lymphoma, 
where both withdrawal of immunosuppression and DLI per se have been shown to induce responses in 
relapse after allogeneic HSCT (Bloor et al. 2008). In a large registry analysis, allogeneic HSCT had 
lower relapse rates in follicular lymphoma when compared to autologous HSCT, but no survival benefit 
occurred as toxicity was higher in the allogeneic group (van Besien et al. 2003). Therefore allogeneic 
HSCT is reserved for multiply relapsed cases with no alternative therapies.  
 In aggressive B-cell lymphomas, such as diffuse large B-cell non-Hodgkin lymphoma, 
allogeneic HSCT is reserved for cases which are chemosensitive but multiply relapsed. Generally this 
occurs in the situation of post-autograft relapses, and is only suitable for a minority of patients at 
present, though long-term cures are reported.  
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 In summary, allogeneic transplant is a useful though toxic treatment for B-cell malignancies, 
and is generally only used in the relapsed/refractory setting. Even in such patients allo-HSCT can result 
in long lasting cures, the presumed mechanism of which is Graft-versus-Tumour. The efficacy of DLI for 
various B-cell malignancies in multiple settings indicates that the effector cell of the immune response 
are T-cells, therefore T-cells are a promising avenue to investigate further for B-cell immunotherapy.  
 
1.3  Adoptive immunotherapy for pathogens after allogeneic 
haematopoietic stem cell transplant 
A brief review of pathogen-specific adoptive immunotherapy follows, in order to place in context the use 
of redirected virus-specific T-cells with chimeric antigen receptors. Allogeneic HSCT is complicated by a 
prolonged state of decreased immunity leading to a risk of opportunistic infections and secondary 
malignancy. Immediately following HSCT there is an aplastic phase where infection risk is similar to 
other profoundly neutropenic patients. This innate host immunity generally recovers rapidly unless there 
is a prolonged time to neutrophil engraftment or mucosal damage. Host adaptive immune memory 
(acquired over a lifetime of vaccine and infectious disease exposure) is destroyed by the transplant 
preparatory conditioning, and replaced by immune cells of donor origin post-transplantation. Donor 
adaptive immunity is not efficiently transferred along with the graft due to low numbers of donor memory 
lymphoid cells containing only a small fraction of the donor’s immune repertoire, further impacted by 
graft T-cell depletion in some settings, and the requirement for post-transplant GvHD prophylaxis which 
is generally directed at suppressing graft T-cells (Molldrem 2005).  
1.3.1 Immune reconstitution after allograft 
The period following allograft myeloid engraftment is characterised by a severe defect in adaptive 
immunity, particularly a cellular immune deficiency. T-cell subsets recover at different tempos following 
allogeneic HSCT, the slowest subset (taking several months at least) is usually the CD4+ T helper cells, 
relying on thymic-dependent maturation from donor haematopoietic stem cell (HSC) derived common 
lymphoid precursors (Seggewiss and Einsele 2010). Thymic-independent T-cell recovery occurs due to 
peripheral homeostatic expansion of passively transferred donor memory T-cells, and although more 
rapid than thymic-dependent pathways there is a limited T-cell repertoire (Molldrem 2005). NK cells 
usually expand early, and the defects in humoral immunity can take years to recover fully, although 
may be treated through passive infusions of immune globulin.  
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Figure 1-5 Immune reconstitution following allogeneic HSCT 
(Molldrem 2005) 
 
As a result of the cellular immune defect and the requirement for immunosuppression for GvHD, the 
risk of opportunistic infections is highest until day +100, then tends to reduce after the restoration of 
normal T-cell numbers, tapering of immunosuppressive drugs, and re-vaccination. The highest risk 
infections include invasive fungal infections (IFIs), pneumocystis jirovecii pneumonia (PJP), and viral 
infections including community respiratory viruses and herpes group viral infections such as 
Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) reactivation. 
 A major research project worldwide is the restoration of normal immunity in HSCT recipients 
without compromise in terms of GvHD or relapse rates. The adoptive transfer of donor derived antigen-
specific cytotoxic T-cells to recipients post transplantation is one attractive strategy with successes in 
early clinical trials reported. 
1.3.2 Virus-specific T-cell immunotherapy 
1.3.2.1  Epstein-Barr Virus adoptive immunotherapy 
EBV, a member of the herpes virus group (HHV-4), is acquired in childhood or adolescence, with 
seroprevalence over 95% of adults worldwide (Taylor et al. 2005). EBV primary infection usually causes 
a benign self-limited polyclonal lymphocytosis followed by latent infection, however reactivation in the 
setting of solid-organ and haematopoietic transplant can lead to the post-transplant lymphoproliferative 
disease (PTLD). EBV-related PTLD treatment generally consists of reduction in immunosuppression, 
and anti-lymphoma treatment. 
 Papadopoulos et al reported the efficacy of donor lymphocyte infusion (DLI) in five adult 
patients with EBV-PTLD (Papadopoulos et al. 1994). The patients received between 0.8–1.0x106 CD3+ 
cells/kg and all responded completely to the DLI, although two patients subsequently died from 
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respiratory failure. Virus-specific T lymphocytes within the leukocyte population were the proposed 
agent for the anti-tumour effects. A subsequent letter by Heslop written in response to the above paper 
outlined the case of a 3 year old boy with juvenile chronic myeloid leukaemia (CML) treated similarly 
with a DLI from an partially HLA matched sibling for refractory EBV-PTLD (Heslop et al. 1994). He 
achieved remission from the PTLD but developed severe GvHD. The case highlighted the dangers of 
using unselected DLI for PTLD treatment, and provided a rationale for the use of EBV-specific cytotoxic 
T lymphocytes in order to preserve the anti-EBV effect of the DLI while removing the danger of DLI 
induced acute GvHD.  
 Building on this research, T-cell cultures of EBV-specific cytotoxic T lymphocytes (CTLs) can 
now be generated from the peripheral blood of EBV-seropositive donors ex-vivo. A phase I clinical 
report of 14 HSCT patients treated at St Jude’s with these EBV-specific CTLs appeared in 1996  
(Heslop et al. 1996). The long-term results for these patients have been published (Heslop et al. 2010). 
One hundred and fourteen patients at three US sites were treated and analysed, none experienced 
adverse infusion reactions. No acute cases of GvHD developed de novo, and transient mild (grade I-II) 
acute GvHD was recorded in only 8 of 51 patients with a prior GvHD episode. 13 patients had EBV-
PTLD at the time of infusion, 2 succumbing subsequently, the remainder entering sustained complete 
remission post infusion. The cost for manufacture and testing each EBV-CTL cell line was estimated at 
US$6095, note that anti-CD20 monoclonal antibody therapy is quoted by the authors as costing 
US$9000 per dose at the time. 
1.3.2.2  Cytomegalovirus-specific adoptive immunotherapy 
In an analogous sense to the EBV-specific CTL therapy described above, CMV-specific CTLs have 
been shown as safe post allogeneic HSCT, with efficacy in terms of reduction in CMV reactivation 
rates. CMV (human herpes virus 5, HHV-5) is a major cause of morbidity and mortality following 
allogeneic HSCT. CMV reactivation is defined as the presence of detectable CMV DNA or antigen in 
peripheral blood without the presence of associated end-organ damage related to CMV, whereas CMV 
disease indicates tissue damage due to virus, such as CMV-colitis or CMV-retinitis. The risk of CMV is 
highest within the first 100 days, identified risk factors for CMV being CMV serostatus mismatch,  acute 
or chronic GvHD, HLA-mismatch, and non-sibling donor (Ljungman 2008). The incidence of CMV 
reactivation was 53.3% in the Australian setting when looking at CMV seropositive recipients (George 
et al. 2010), and CMV serostatus is an independent adverse pre-transplant variable for non-relapse 
mortality (Nichols et al. 2002). 
 The earliest clinical trial using CMV-specific CTLs for immune reconstitution was reported from 
the Fred Hutchison Cancer Research Center in Seattle, Washington (Walter et al. 1995). CMV-specific 
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CTLs manufactured ex vivo were infused 30 days post-transplant in 14 patients. No serious adverse 
infusion reactions were recorded, and there were no GvHD flares in those patients with prior GvHD. 
Transient mild acute GvHD occurred de novo in three patients. None of the patients developed CMV 
viraemia or disease following infusion, and all 14 patients reconstituted CMV-specific cytotoxic T-cells 
by day 50, compared to an untreated control group with the same regimen in which 50% still lacked 
CMV immunity at day 50. 
 Another (Australian) early phase clinical trial report demonstrated the safety of prophylactic 
polyclonal CMV-specific CTLs using an alternate CTL generation method (Micklethwaite et al. 2008). In 
this case monocyte-derived dendritic cells (MoDCs) were generated from the peripheral blood of CMV 
positive HSCT allograft donors, then pulsed with an adenoviral vector encoding the immunodominant 
CMV matrix protein pp65. The MoDCs were irradiated then incubated with autologous PBMCs, and 
expanded in IL-2 over a three week period.  In the 12 patients treated there were no infusional adverse 
events noted, GvHD rates were not increased, and CMV specific immunity was confirmed in all 12 
patients by ELISPOT analysis. No patients required CMV antiviral therapy over the course of follow up. 
 Non-culture based CTL selection technologies are another way to generate the virus specific 
CTLs, and have shown very encouraging results in early trials. Feuchtinger et al reported on 18 
patients with either HLA haploidentical donor or Matched Unrelated Donor (MUD) transplants and 
refractory CMV, who were infused with CMV-CTLs isolated using a technique called IFN-γ capture to 
isolate CMV-reactive T-cells (Feuchtinger et al. 2010). After infusion of a mean CD3+ dose of 
21x103/kg (which is a very low cell dose), 83% either completely cleared or markedly reduced their 
CMV load, with no infusion reactions or GvHD reported. A related approach reported from Birmingham 
is the use of MHC-tetramers with bound CMV epitopes (referred to as tetramers hereafter) for magnetic 
bead capture of CMV specific T-cells (Cobbold et al. 2005). 8 of 9 patients cleared their refractory CMV-
viraemia with this approach, again with safe infusions and no serious GvHD attributable, and a very 
quick process of CTL generation. Tetramers are necessarily restricted to patients with certain HLA-
types, limiting their generalisability. A randomised trial is currently accruing in Europe using CMV-CTLs 
generated through multimer or IFN-γ based selection (ClinicalTrials.gov identifier NCT01077908). 
1.3.2.3  Multivirus-specific adoptive immunotherapy 
The success of monovirus-specific CTLs post transplantation has led many groups to investigate the 
possibility of developing CTL cultures reactive to multiple viruses. One illustrative report from Leen et al 
used an Adenoviral vector loaded with CMV pp65 protein (Ad5f5-CMVpp65) to infect EBV driven 
lymphoblastoid cell lines as stimulators for donor PBMCs (Leen et al. 2006). The T-cell cultures thus 
generated showed functional in vitro responses to irradiated EBV-LCLs and CMV-peptide in all cases, 
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and to adenoviral peptide in most. Eleven patients were then infused post-HSCT, no infusional toxicities 
or GvHD developed, and all patients developed evidence of multi-virus reactivity in PBMCs post 
infusion.  
There is no particular reason why CTL cultures must be limited to only three viruses, other 
groups are researching different multi-virus combinations incorporating Varicella-Zoster virus, BK 
polyoma virus, and influenza amongst others, including the Westmead Millennium Institute cell therapy 
group. 
1.3.2.4  Third party virus-specific T-cells 
The apparent lack of GvHD risk for CTL infusions post allogeneic HSCT, as well as the difficulty and 
labour intensity of generating CTLs for individual patients, has led to the investigation of third-party 
virus-specific CTLs as a form of ‘off-the-shelf’ T-cell therapy. Such third-party CTLs would be unlikely to 
be fully HLA-matched, however in the evidence to date there does not appear to be an excess risk of 
GvHD in this situation. One such bank of third-party EBV-specific CTLs has been established in 
Scotland, for use in EBV-positive PTLD refractory to standard treatments (Haque et al. 2007). Using a 
‘best HLA-match available’ policy, 2 to 3 EBV-CTLs are thawed for each potential recipient. The CTL 
line with the highest specific killing of recipient LCLs and with the lowest killing of recipient PHA-blasts 
was selected for infusion. Survival after 6 months was 79%. No adverse events were reported. They 
were able to trace the CTLs in only 3 patients, none were detectable beyond 7 days after each infusion.  
 A related concept is the use of third party multivirus-specific CTL banks, several of which are 
now established. Leen et al have reported on their experience of treating 50 HSCT recipients with 
refractory EBV, CMV, or adenoviral infections (Leen et al. 2013). The response rate was 74% for the 
whole group, only 4 of whom developed recurrence or progression, and only 2 of whom developed de 
novo GvHD after CTL infusion. This promising approach is now under evaluation locally at Westmead 
Millennium Institute. 
 
1.3.3 Alloreactivity in antigen-specific cytotoxic T-cells 
One of the original concerns that has so far failed to eventuate is that of inducing serious GvHD after 
infusion of virus-specific CTLs by means of passenger alloreactive T-cells. Almost all the trials to date 
have used polyclonal T-cell cultures with a theoretical concern of transferring deleterious T-cells as well 
as the specific cells. No group so far has reported an excess risk of GvHD following CTL infusion. 
 The best laboratory based method for predicting risk has generally been thought to be 
alloreactivity assays, performed by most groups to date as part of release criteria for the CTL product. 
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This may be done by various methods including ‘standard’ cytotoxicity assay by 51Cr release 
(coculturing donor CTLs with recipient cells such PHA-blasts), or IFN-γ release. One group has gone 
further, testing for HLA-specific alloreactivity in 11 virus-specific monoclonal T-cell cultures, finding 45% 
of the virus specific T-cell clones to be cross-reactive to HLA-antigens (Amir et al. 2010). By means of 
T-cell receptor (TCR) gene transfer from 2 of the clones they were able to demonstrate that the allo 
HLA-reactivity and virus specificity came from the same TCR. Though this cast a pall over the safety of 
HLA-mismatched virus-specific CTLs, there is no clear correlation between CTL HLA alloreactivity as 
measured by lab techniques with clinical risk of GvHD. Melenhorst et al have subsequently reported the 
outcomes of 73 patients infused with HLA-mismatched virus-specific CTL cultures (Melenhorst et al. 
2010). No patient developed GvHD as a result of infusion. They went on to test four of the CTL lines 
already infused and found all of them demonstrated in vitro alloreactivity to some extent. This is 
reassuring even if the lack of in vivo to in vitro correlation is not well understood. The authors 
suggested several possible explanations: there may be discordance in HLA-expression in GvHD target 
tissues compared with the in vitro stimulator cells; GvHD reactive T-cell lines may have a limited 
capacity to expand in vivo; or the predominance of committed memory effector T-cells in the culture 
may be protective. 
1.4 Adoptive cellular immunotherapy for cancer 
Research into adoptive cellular therapies for cancer has paralleled the development of antigen-specific 
CTLs for viral pathogens. Underlying the rationale for cancer specific T-cell immunotherapy is the 
observation that T-cells can cure cancer in some settings. In particular, the Graft-versus-Leukaemia or 
Graft-versus-Lymphoma (GvL) effect is mediated primarily through T-cells. Observations supporting this 
include the cure of CML and other haematological malignancies through donor lymphocyte infusions 
(Kolb et al. 1990), and the higher relapse risk seen in T-cell depleted grafts compared to unmanipulated 
grafts (Champlin et al. 2000). In addition there is a very clear link in certain viral-driven post-transplant 
malignancies as demonstrated by EBV-CTLs discussed above. 
1.4.1 The Graft-versus-Lymphoma/Leukaemia Effect 
Knowledge of the existence of the GvL effect has been present from the earliest studies of human 
allogeneic transplantation, and evidence lies primarily in the observations that (i) relapse risk after 
allogeneic HSCT is markedly reduced in the presence of GvHD compared to without GvHD (Weiden et 
al. 1979), and (ii) infusion of donor lymphocytes without any additional chemotherapy or manipulation 
can induce remissions in relapsed leukaemias (Kolb et al. 1990). However, there is also evidence that 
the GvL effect can be present without GvHD in some cases, leading to the major research effort 
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worldwide into disentangling the GvHD effect from the GvL response. Specific adoptive cellular therapy 
is one aspect of this research program. One source of evidence for the fact that GvL can be separated 
from GvHD is the observation that HLA-matched allo HSCT recipients without GvHD still have a lower 
relapse risk than either syngeneic transplantation or autologous transplantation (Horowitz et al. 1990). 
 The main effector cells of the Graft-versus-Leukaemia effect are donor derived T-cells specific 
for either minor Histocompatibility Antigens (mHAs) or Tumour Associated Antigens (TAAs). Progress 
has been made in targeting T-cells towards these antigens for specific cell therapy. In other 
circumstances NK-cells have also been shown to exert anti-tumour responses, approaches using these 
cells will be presented briefly. 
1.4.2 Minor Histocompatibility Antigens 
Minor Histocompatibility Antigens are immunogenic peptides which are thought to originate from the 
approximate 90000 non-synonymous single nucleotide polymorphisms (SNPs) present within the 
human genome (Bleakley and Riddell 2011). In the setting of HLA-matched HSCT mHAs take the form 
of peptides presented within host MHC class I or II, recognised by donor T-cells as foreign. As opposed 
to self-antigens expressed in tumour cells recognised by autologous T- cells, the donor T-cell 
recognition of mHAs tends to be high-avidity due to the allogeneic nature of the peptide.  
The greatest danger in targeting therapies towards mHAs is that of inducing GvHD. In order to 
abrogate the risk of GvHD efforts have turned towards defining the small subset of mHAs exclusively 
expressed in haematopoietic cells, of which ~30 have now been defined (Akatsuka et al. 2007). The 
first characterised and best known of these haematopoietic-restricted mHAs were HA-1 (from the gene 
HMHA1) and HA-2 (from gene MYOG1), both of which are presented by HLA-A*0201. DLI from HLA-
A*02 donors negative for HA-1 and/or HA-2 into positive recipients with relapsed CML can cure the 
disease without GvHD developing, as shown by Marijt et al who showed the emergence of HA-1 and 
HA-2 specific CTLs after successful DLI in 3 patients, clones of which were cytotoxic to recipient 
derived CML lines in vitro (Marijt et al. 2003). Unfortunately the estimated frequency disparity for HA-1 
is only 6.6% for sibling pairs. In addition any particular mHA is HLA-restricted, meaning that mHA 
mismatched recipient-donor pairs are likely to remain an option only for the minority of transplants. 
However more and more haematopoietic-restricted mHAs are being defined every year (see Figure 1-
6). 
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Figure 1-6 The accelerating pace of discovery of minor histocompatibility antigens.  
(Bleakley and Riddell 2011) 
 
 
 
1.4.2.1 Targeting minor histocompatibility antigens by immunotherapy 
Culturing or selecting mHA-specific T-cells from donors in an analogous fashion to virus-specific CTLs 
is an attractive approach under investigation in several centres worldwide. To date only one Phase 1 
trial has been reported, by investigators at the Fred Hutchison Cancer Research Center (Warren et al. 
2010). Five out of 7 patients achieved complete, though transient, responses, with a lack of persistence 
of transferred cells identified as the main reason for relapse. In addition they found pulmonary toxicity in 
three patients, which correlated with unexpected tissue expression of the mHA-encoding genes. The 
lab process for generating the mHA-specific CTLs was laborious. Less intensive manufacturing 
techniques for generating mHA-specific CTLs include direct selection with MHC-multimers and CTL 
redirection with artificial TCRs or CARs (discussed later).  
The other approach to target mHA would be to vaccinate donors against mHA prior to stem cell 
donation or CTL collection, as a means of augmenting the GvL immune response. This certainly has 
merit in murine models (for example (Li et al. 2011)), but is yet to be tested in human trials. The ethics 
of vaccinating donors with alloantigen may prove a stumbling block to this approach initially. 
1.4.3 Tumour-associated antigens 
Almost any protein which is mutated or over-expressed in tumour cells may serve as a potential 
immuno-therapeutic target for immunotherapy. In practice many such proteins have been identified 
already, examples of which include CD19 in B-cell NHL and the BCR-ABL gene product in CML. 
Although Tumour-associated antigen (TAA) reactive T-cells have been postulated to be the other major 
effector cells of the GvL effect, the majority of the GvL effect is probably induced by allo-antigens, not 
TAAs.  
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The ideal TAA for immunotherapy would be universally expressed on tumour cells, absent on 
normal cells, and highly immunogenic. In practice no such TAA has yet been identified, though some 
do come close. The top ranked TAA by the US National Cancer Institute was the Wilms-tumour protein, 
encoded by the gene WT-1 (Cheever et al. 2009). The general principle for targeting these TAAs with 
adoptive immunotherapy is to develop CTLs reactive to single or multiple TAAs from autologous or 
donor derived T-cells, in a fashion analogous to virus-specific CTL cultures described previously. 
However, in practice, TAAs from tumours arising in immunocompetent hosts tend to be poorly 
immunogenic due to factors such as poor affinity and host immune system evasion, hence the interest 
in redirecting T-cell specificity which will be discussed in the next section. Nonetheless efforts have 
been made to develop TAA-specific CTLs through tissue culture, of which a few will be reviewed briefly.  
The Wilms’-tumour gene was first described in 1990, ironically first noted to be a tumour 
suppressor as its inactivation led to the development of Wilms’ tumours, a rare paediatric renal cancer 
(Keilholz et al. 2005). Subsequently its gene product WT1 has been found to be highly overexpressed 
in AML blasts, as well as many non-haematopoietic malignancies, though with little baseline expression 
in normal adult tissue (Ramani and Cowell 1996). Active research areas of WT1 include its role as a 
marker of minimal residual disease in AML, its prognostic implications, but also its potential as an 
immunotherapeutic target. As WT1 is predominantly an intranuclear antigen it is not readily amenable 
to monoclonal antibody targeting. Active immunotherapy techniques are used instead, including 
immunisation with WT1 peptides or whole antigen, or dendritic cell based vaccines where autologous 
dendritic cells are pulsed with antigen ex-vivo then administered to patients. There have been several 
positive case reports and early phase studies reported with all these approaches, and larger trials are 
underway (Keilholz et al. 2009, Van Tendeloo et al. 2010, Ochsenreither et al. 2011). 
 Selecting and expanding autologous WT1 specific T-cells from leukaemia patients is likely to 
be fruitless as it does have low level expression in normal tissue, and hence high avidity reactive T-
cells are edited out within thymic maturation. Therefore most approaches to date have focused on 
isolating WT1 reactive T-cells from the peripheral blood of normal donors and expanding these for 
adoptive immunotherapy.  
 PRAME, standing for ‘preferentially expressed antigen of melanoma’, is another TAA of 
potential therapeutic importance in Haematologic malignancies. PRAME is a cancer-testis antigen, with 
low/absent expression on normal haematopoietic cells. PRAME is immunogenic, as demonstrated by 
the presence of PRAME-specific CTLs in the blood of cancer patients, in fact PRAME was first 
recognised as a TAA as it encoded an HLA*A24 restricted peptide from melanoma cell lines recognised 
by autologous T-cells from the relevant patient (the method is called ‘T-cell epitope cloning’). 
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 Expanding autologous PRAME-specific T-cells can be achieved in a variety of ways. Recently 
Quintarelli and colleagues at the Baylor College of Medicine (Houston, TX) published a technique 
resulting in high-avidity HLA-A*02 restricted CTLs for PRAME from the blood of normal donors and 
those with PRAME+ positive malignancies (Quintarelli et al. 2011). The authors identified a previously 
unreported highly immunogenic epitope resulting in CTLs of high avidity and in vitro functionality from 
normal donors and those with haematologic malignancies, which are now entering clinical trials. 
1.4.4 Natural Killer cell adoptive immunotherapy approaches 
There are several other cell types of potential importance for adoptive cell therapy apart from T-cells, 
including NKT-cells and γδ-T cells, but the furthest advanced at this point is the use of Natural Killer 
cells (NK-cells). NK-cells are members of the innate immune system derived from a common 
lymphocyte precursor, but lacking the T-cell receptor or CD3 complex. They are recognizable 
morphologically as large granular lymphocytes, and they play a role in viral and tumour immunity largely 
through a class of surface receptors termed ‘killer immunoglobulin-like receptors’ (KIRs). In the setting 
of T-depleted haploidentical transplantation, where donors and recipients are mismatched by one HLA 
haplotype, NK alloreactivity from donor to recipient plays a very strong role in determining outcome in 
patients with AML (Ruggeri et al. 2002). In particular, there is a beneficial outcome on relapse rates 
without affecting GvHD where there was a missing KIR ligand (on the mismatched HLA-haplotype) in 
the recipient compared to the donor. There are no standard methods to predict NK alloreactivity as of 
yet,  but the simplest would appear to be comparing KIR-ligands in donor and recipient as defined by 
class I HLA typing, called the ‘missing-ligand’ model, however this approach may miss many cases of 
NK alloreactivity between donor and recipient.  
1.4.5 Adoptive cellular immunotherapy for cancer - summary 
The goal of separating GvL from GvHD led to the identification of T-cells as the predominant 
component underlying both effects. One of the main immunological differences between HLA matched 
donor and recipient pairs is the presence of minor Histocompatibility Antigens, which are likely to be the 
dominant players in GvHD and GvL through alloreactivity. The priority for tumour immunotherapy in this 
area is the identification of haematopoietic restricted mHAs for targeting with specific CTLs, though to 
date pairs mismatched solely at such mHAs are likely to be rare. 
 Tumour specific antigens are a more attractive option in many ways, but targeting TAAs with 
autologous cellular therapy is hamstrung by the poor avidity of expanded CTLs, though with some 
exceptions as discussed above. Allogeneic TAA-specific CTLs can be highly avid but face the potential 
risk of CTL-vs-Host.  
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The method of generating these TAA- or mHA- specific T-cells is highly individual and not 
amenable to selection techniques due to low precursor frequencies, unlike the virus specific CTL story. 
The applicability of ‘off the shelf’ third-party banks to tumour-specific CTLs is likely to be hard to 
demonstrate unless techniques to bypass alloreactivity can be demonstrated. The particular niche 
where TAA-specific CTLs are likely to remain relevant to immunotherapy is that of targeting intracellular 
antigens, which are otherwise only targetable by cytotoxic chemotherapy or small molecules, but not 
monoclonal antibodies. 
The enormous potential of harnessing T-cells to treat malignancy, coupled with the inherent 
risks and difficulties of generating tumour-reactive T-cells as outlined above, has led to the 
development of genetic engineering for ‘redirection of specificity’ techniques which will be discussed 
further in the next section. 
  
1.5 Redirecting T-cell specificity with Chimeric Antigen Receptors 
T-cells are potent mediators of anti-tumour responses in haematopoietic malignancies, melanoma, and 
several other cancer types, as has been demonstrated in previous sections. However the broad 
applicability of using T-cells to target cancer as a form of passive immunotherapy has been hampered 
by multiple concerns. These include the concerns that the unselected transfusion of T-cells from 
healthy donors by DLI is fraught with the risk of GvHD, and the use of T-cells either selected or grown 
with TCR specificity for a given antigen has limitations in terms of cost and general applicability. 
Tumour infiltrating lymphocytes (TILs) in the melanoma setting are costly to manufacture, and must be 
administered with high doses of chemotherapy. Allogeneic T-cells selected to target minor 
histocompatibility antigens are hard to manufacture, are highly alloreactive (unless the mHA tissue 
expression is restricted to certain lineages), and are restricted by recipient HLA-type. Autologous T-
cells selected for specificity against tumour antigens are generally of low avidity, as high avidity T-cells 
are edited out by thymic T-cell maturation processes. 
 The next sections detail some approaches used to overcome some of the difficulties of 
harnessing T-cells to fight cancer, through using gene therapy techniques to redirect T-cell specificity 
towards an antigen of interest. Although it is also possible to redirect T-cell specificity by using artificial 
T-cell receptors (TCRs), this review focuses on the use of chimeric antigen receptors (CARs) for T-cell 
redirection, which confer the specificity of a given monoclonal antibody onto T-cells. The benefits of 
conferring antigen specificity of interest into T-cell cultures include the ability to target tumours directly 
with T-cells without limitation in respect of HLA-type, with high avidity, with a low risk of GvHD, and 
without laborious ex vivo culturing methods.   
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1.5.1 Biology of the T-cell receptor 
In order to understand the concepts of T-cell redirection with CARs the biology of the T-cell receptor will 
be reviewed briefly. The antigen specificity of a T-cell is determined by the unique T-cell receptor 
expressed on the cell surface. The structure of the natural T-cell receptor includes a heterodimer of two 
chains which are complexed to CD3, a structure which functions to transmit signals from the TCR into 
the cytoplasm (Figure 1-7). CD3 consists of several different chains including two pairs each of CD3ε, 
CD3γ, CD3δ, all of which have an extracellular domain and short cytoplasmic tail, and a pair of CD3ζ 
chains, also known as CD247, which conversely has a short extracellular domain and long cytoplasmic 
tail. The CD3 complex is activated via 10 cytoplasmic located ITAMs (immunoreceptor tyrosine-based 
activation motifs), three of which are located on each CD3ζ, and CD3ζ is hence crucially important for 
activation of T-cells. The whole TCR complex recognises antigens presented within the MHC complex, 
which is present as MHC class I on all cells, and MHC class II which is present only on professional 
Antigen Presenting Cells.    
 
 
Figure 1-7 T-cell receptor structure.  
The TCRαβ heterodimer is complexed with CD3 chains, which are activated through ITAMs, thereby 
coupling the TCR to downstream signalling cascades. (Schumacher 2002) 
 
 The majority of TCR chains are αβ, but a small proportion (1-5%) are γδ chains which have 
less diversity. The hypervariable antigen binding regions of each TCR chain, also known as the 
Complementarity Determining Regions (CDRs), are developed within pre-T-cells within the thymus in 
an analogous fashion to the development of the B cell receptor and antibody formation (see Figure 1-
8). The most variable region is CDR3, which is responsible for the majority of peptide binding 
recognition (Davis 1990). For TCRβ, germline DNA is rearranged during T-cell development by random 
rearrangement of V, D, and J segments. For TCRα, germline DNA is rearranged between V and J 
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segments only (skipping the TCRδ genes inside). The resultant highly polymorphic chains have a 
variable and constant region, with the CDR regions defined by junctions between the relevant VDJ 
recombination (Szymczak and Vignali 2004). Unlike the equivalent VDJ recombination in antibody 
development there is no somatic hypermutation thereafter.  
 
 
Figure 1-8 TCRβ rearrangement. 
Segments from the TCRβ gene are rearranged randomly to determine the hypervariable CDR regions, 
which then confer antigen specificity in conjunction with a TCRα chain. From (Szymczak and Vignali 
2004) 
   
 There are numerous gene segments available for VDJ recombination, and in addition the 
joining process of the different VDJ segments is imprecise, and often leads to nucleotide addition or 
deletion (‘P’ and ‘N’ nucleotides), which increases diversity even further. The D segments of the Vβ 
chain are often skipped or read in different frames, and hence in total there is enormous TCR receptor 
diversity available, estimated as up to 1018 different combinations (see Figure 1-9).    
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Figure 1-9 Immunoglobulin and TCRαβ diversity in humans.  
(Janeway et al. 2001) 
 
 
 T-cell activation is not only dependent on TCR interaction with cognate antigen, but also with 
costimulatory signals. T-cell costimulation and activation is incompletely understood, but it is well 
recognised that T-cell engagement with APCs which do not express the appropriate costimulatory 
signals leads to T-cell anergy (Harding et al. 1992). Costimulatory signals generally take the form of 
alternate membrane bound glycoproteins expressed by T-cells interacting with ligands expressed by 
activated antigen presenting cells (APCs). Some of these costimulatory molecules include CD28, which 
is the only known costimulatory molecule to be expressed by naive T-cells, and which interacts with the 
‘B7’ class ligands CD80 and CD86, which in turn are expressed by APCs exposed to Toll-like receptors 
and other activating signals (Bour-Jordan and Bluestone 2002). Others include inducible T-cell 
costimulatory receptors such as OX40 and the 4-1BB molecule, also known as CD137 or the TNF 
receptor superfamily member 9. 4-1BB interacts with a high affinity 4-1BB ligand that is present on a 
variety of APCs, and is preferentially expressed in CD8 cells (Vinay and Kwon 2012). OX40 is similar to 
4-1BB in that it is a TNF receptor superfamily member which is inducible in T-cell activation and 
interacts with OX40-ligand on the surface of activated APCs (Ishii et al. 2010). The exact role of these 
costimulatory signals on the development and activation of different T-cell subsets is not well 
understood. 
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1.5.2 Chimeric antigen receptors 
Chimeric Antigen Receptors (CARs) are single chain proteins derived from elements of monoclonal 
antibodies, the TCR signalling complex, and T-cell activation signals, which confer specificity of that of 
the parent monoclonal antibody when expressed within T-cells. A schematic of CAR design is 
presented in Figure 1-10. Common features in CAR design include (i) a single chain variable fragment 
(scFv) from a monoclonal antibody directed towards the antigen of interest; (ii) a hinge region 
connecting the scFv to the transmembrane and intracellular domains; (iii) one or more activating 
domains from costimulatory molecules, such as CD28 or 4-1BB; and (iv) either the CD3ζ-chain or 
FcRγ, which act as signal transduction elements for T-cell activation. Functionally, the scFv portion 
serves to target the CAR to an antigen of interest, and the remaining elements serve to transmit T-cell 
activation signals into the cytoplasm in an analogous fashion to native TCR engagement and 
costimulation. So long as the DNA sequences of the VH and VL segments are known, an scFv may be 
constructed from any mAb. The enormous potential of CAR design and function lies in the modularity 
inherent in the choice of scFv towards any antigen to which mAbs can be raised, in conjunction with 
numerous choices for costimulatory domains and signalling tails.  As CARs are a single chain construct, 
in general measuring ~2kb in length, they can be expressed from a number of vectors either transiently 
or integrated permanently into the DNA of T-cells by means of transposase or retroviral genetic 
engineering systems.  
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Figure 1-10 Chimeric Antigen Receptors 
Chimeric Antigen Receptors consist of a single chain fragment from a monoclonal antibody, coupled 
with a hinge region, transmembrane and intracellular signalling domains which usually derive from the 
CD3ζ chain. Later generations of CARs incorporated the intracellular costimulatory domains from one 
(second generation) or two T-cell costimulatory molecules (third generation). Figure from (Maus et al. 
2014). 
 
1.5.3 Chimeric antigen receptor history and development 
‘Chimeric immunoreceptors’ were first developed by several groups in the late 1980s as a tool to endow 
T-cells with the specificity of a monoclonal antibody in a non-MHC restricted way, both to investigate 
concepts behind activation of T-cells through the TCR complex, and as a potential avenue in cell 
therapy. Leading up to the first CAR descriptions were several reports of fusion chimeric proteins which 
combined the variable domain of the TCR α chain with the constant coding regions from 
immunoglobulin genes (Gascoigne et al. 1987). Given that the connections between the V and C 
regions of immunoglobulin genes are homologous to that of TCR genes, several groups then 
demonstrated the first chimeric T-cell receptors by reversing this approach, and instead coupling the 
variable fragments from mAbs (the VH and VL segments) with the constant domains of the TCR α and β 
chains (Kuwana et al. 1987, Gross et al. 1989, Gross et al. 1989). Such chimeric immunoreceptors, 
which they labelled as ‘T-bodies’, were double-chain chimeric receptors which interacted functionally 
through the native CD3 complex (see Figure 1-11). Double chained chimeric immunoreceptors 
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conferred monoclonal antibody specificity to T-cells in a non-MHC restricted manner, but also faced the 
same issues inherent to artificial TCR insertion, mainly that of poor transgene expression due to  the 
need to introduce two transgenes, and also interference of expression due to mispairing with the native 
TCR chains.   
 
 
Figure 1-11 The first chimeric immunoreceptors 
Chimeric immunoreceptors, or ‘T-bodies’, were initially formed by combining the variable fragments 
from parent monoclonal antibodies with the constant regions of the T-cell receptor α and β chains. 
Figure adapted from (Eshhar 2014). 
 
 Single chain CARs were developed in order to overcome the issues of poor transgene 
expression with the initial chimeric immunoreceptors. The key enabling technology was the 
demonstration that single chain variable fragments (scFvs, mentioned throughout this review, see 
Figure 1-4) have the same specificity and affinity as the parent monoclonal antibody, but are encoded 
as a single chain and are only a fraction of the length of the parent monoclonal (Bird et al. 1988). The 
first single-chain CAR was reported in 1993 by a group from the Weizman Institute of Science in Israel 
(Eshhar et al. 1993). In this paper the authors demonstrated successful development and antigen-
specific activation using an anti-2,4,6-trinitrophenyl (TNP) antibody scFv connected to either the CD3ζ 
chain or FcRγ (see Figure 1-12). The first antitumour-specific CARs, which demonstrated anti-tumour 
activity in vitro, were then developed shortly thereafter.  
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Figure 1-12: Expression vector from Eshhar et al, 1993 
The first single chain CAR, termed the scFvR, had an scFv combined with the human FcRγ chain 
activation domain. There was also a κ light chain leader element (Lκ), G418-resistance gene (neor), 
simian virus 40 origin of replication (SV40 ori), and the Long Terminal Repeat (LTR) promoter element 
of the Rous sarcoma virus (RSV). The γ chain was interchangeable with the CD3ζ chain, which is 
standard on all current CAR designs currently. (Eshhar et al. 1993)   
 
 The first generation of CAR designs did not include costimulatory elements which are 
necessary for full T-cell activation, and without which redirected T-cells become anergised/exhausted. 
Early CAR trials demonstrated no clinical response, perhaps due to this lack of costimulation (Kershaw 
et al. 2006).  Further ‘generations’ of CAR development refer to the incorporation of one (second 
generation) or more (third generation) costimulatory domains after the scFv which serve to improve T-
cell activation, function, and persistence (see Figure 1-10). Although there are multiple costimulatory 
proteins under assessment, at present the two commonest costimulatory domains included in CAR 
design are those of CD28 and 4-1BB. CD28 costimulation is essential to prevent T-cell anergy after 
antigen stimulation (Harding et al. 1992). The intracellular portion of CD28 is short, only 40 amino acids 
in length, and the truncation thereof was shown to complete costimulatory signal transduction, yet 
inclusion of this cytoplasmic tail in a chimeric construct linked to CD8 was sufficient to deliver 
costimulatory signalling (Stein et al. 1994). Chimeric CD28 receptors expressing scFv and CD28 (but 
not the CD3ζ) chain acted as functional receptors without interacting negatively with endogenous CD28 
or TCR, and ‘double transfectants’, expressing both scFv-28 and scFv-CD3ζ, demonstrated synergistic 
activity in terms of IL2 secretion (Alvarez-Vallina and Hawkins 1996). By combining the CD28 signalling 
and transmembrane domains in line with a first generation CAR targeting CD33, a UK based group 
were able to demonstrate 20-fold increased IL2 production on stimulation when compared to their 
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original construct, without adversely affecting CAR expression (Finney et al. 1998). This was the first 
demonstration of provision of both a primary and secondary/costimulatory signal in the same single-
chain construct, and came to be termed as the ‘second generation’ of CAR design. Later groups have 
incorporated CD28 domains demonstrating markedly improved function and resistance to Treg 
inhibition (Loskog et al. 2006), and confirming that the included CD28 domain works even in CD28-
knockout clones, and is therefore independent of native CD28 costimulation (Kowolik et al. 2006). 
Several other costimulatory molecule domains have been added to CARs and compared to, or 
combined with, CD28. Of these one of the most widely used at present is 4-1BB, otherwise known as 
CD137. 4-1BB is a TNF family receptor transmembrane glycoprotein which acts as a costimulatory 
signal in activated T-cells. Although initially found to be a weaker costimulatory signal than CD28, it was 
subsequently shown to have advantages in terms of anti-tumour efficacy and persistence in mouse 
models over CD28 (Finney et al. 2004, Milone et al. 2009, Tammana et al. 2010). 4-1BB CARs are 
usually combined with the transmembrane domain from the CD8α chain, as opposed to CD28 alone in 
second generation CD28 containing CARs (Maus et al. 2014). Combining both CD28 and 4-1BB 
(amongst others) into a single construct provides two separate costimulatory signals on the one 
construct with synergistic effects in vitro (Carpenito et al. 2009, Tammana et al. 2010). These so called 
‘third generation’ CARs are not widely used in clinical trials as yet, and may have some disadvantages 
over the second generation constructs, with potential exhaustion of transfected T-cells due to 
overstimulation, and some evidence that a second stimulation provides no intrinsic advantage over 
CD28 alone at least in some studies (Hombach et al. 2013). It is important to note that the addition of 
costimulatory domains is not the only enhancement to CAR design, as other elements such as the 
hinge and transmembrane portions, and of course the antigen target per se are likely to be important 
for function and persistence also. 
 
1.5.4 Redirecting T-cells to target B cell malignancy 
B-cell malignancies are a promising target for CAR-redirected T-cells. B-cell malignancy has been 
discussed more fully above, but in brief T-cells have innate activity against B-cell malignancies when 
administered in the form of HSCT or DLI, and furthermore the B-cell surface is replete with many scFv 
targetable antigens with expression restricted to B-cells. CD20 mAbs have already reached the clinic in 
the form of rituximab, but as yet there are no routinely available CD19+ directed immunotherapies. 
Therefore CD19 has become a major target of interest for CAR-redirection in the area of B-cell 
malignancy immunotherapy.  
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 Various groups have commenced clinical trials in patients with B-cell malignancies with variable 
success reported so far. There are many different variables to be assessed with CAR trials, and each 
group has a different take on what is likely to be the optimal approach. Amongst the innumerable 
unanswered questions for CD19-CAR design are: the optimal gene transfer technique; the optimal CAR 
signalling tail design; what is the best promoter to use; the source of T-cells (i.e. autologous vs 
allogeneic); the optimal T-cell subset to redirect; the role of pre-CAR lymphodepleting chemotherapy or 
post-infusion cytokine support; and whether persistence of CAR T-cells is necessary or desirable. 
Some of these issues are addressed later in this review or in our results, but a brief review of the 
approaches of two of the main players is presented here. Although both groups use autologous T-cells, 
with pre-infusion chemotherapy, the University of Pennsylvania group use a lentivirus encoding a 
CD19-CAR with a 4-1BB costimulatory domain, and the NIH group use a retrovirus encoding a CD28 
domain. 
 The use of the CD19-directed CAR in autologous T-cells with a 4-1BB costimulatory domain 
has been pioneered by Professor Carl June and colleagues from the University of Pennsylvania 
(Philadelphia, PA). Their first case report of remission induction and possible cure in 2 out of 3 patients 
with advanced CLL was published in 2011 with intense media interest, and is illustrative of both the 
promise and pitfalls of therapy with CD19-directed CAR (CD19-CAR) therapy (Kalos et al. 2011, Porter 
et al. 2011). Their first reported case was that of a 64 year old male patient with multiply relapsed CLL 
(p53 deficient which portends for chemotherapy refractoriness) (Porter et al. 2011). The authors 
collected autologous PBMC using apheresis which were then transduced by a self-inactivating lentivirus 
with a CD19-directed CAR which contained the scFv from the CD19-specific monoclonal FMC63, a 4-
1BB costimulatory cytoplasmic domain and the promoter from the human gene elongation-factor-1α 
(EF1α). Four days following chemotherapy with pentostatin (aimed at lymphocyte depletion) the patient 
received 3x108 T cells over three days, of which 5% were transduced by CAR (CAR T-cells), for a cell 
dose of 1.46x105 CAR T-cells per kg. Though there were no immediate adverse effects, the patient 
then developed a severe cytokine release syndrome (CRS) and tumour lysis syndrome (TLS), which 
necessitated hospitalisation. By day 23 there was no detectable CLL cells in the patient’s bone marrow, 
and the remission was sustained for 10 months by the time of the initial case report, with persistent 
detection of the CAR T-cells by sensitive PCR testing, and persistent B-cell aplasia. A simultaneous 
case series of three patients treated on this trial was also reported, one case of which was already 
reported as above (Kalos et al. 2011). Two out of the three patients had an identical course, and the 
third reached a partial remission only, with a lack of persistence of the adoptive cells. Given the initial 
remarkable responses the University of Pennsylvania (‘UPenn’) group have expanded their program to 
include other B-cell malignancies. B-cell ALL is perhaps the most striking success so far, with patients 
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achieving durable remissions even after relapses from other promising agents such as blinatumomab. 
The initial case report on two patients demonstrated complete remissions in both, associated with a 
severe CRS and persistent B-cell aplasia (Grupp et al. 2013). In follow up one patient relapsed with a 
CD19-negative ALL clone, and the other remains in remission. Intriguingly CD19-CAR T-cells could be 
detected in the cerebro-spinal fluid (CSF) of one of the patients, indicating that CAR-T treatment may 
reach ALL sanctuary relapse sites such as the CNS. A follow up report of the 30 patients treated so far 
revealed a complete response rate of 90%, with an event-free survival rate at 6 months of 67% (Maude 
et al. 2014). All responding patients had a CRS, with the severity correlating with disease burden at the 
time of cell infusion. Of the 7 patients who relapsed after initial CR, 3 relapses occurred after loss of 
detectable CAR T-cells, and those relapses were preceded by return of peripheral blood B-cells, 3 
others relapsed with a CD19-negative ALL clone, and one relapsed with CD19+ ALL despite 
persistence of CAR T-cells. Abstract presentations from the recent 2014 American Society of 
Hematology annual meeting indicate that the responses in ALL appear to be better than that in CLL, 
with the CLL response rate being 22% CR and 17% PR, for an ORR of 35% (Porter et al. 2014). Early 
data on their NHL program indicates a durable response rate of 50% (Schuster et al. 2014).  
 Professor Rosenberg’s group at the National Institutes of Health (Bethesda, MD) use an 
approach with a CAR encoding for CD19 specificity and CD28 costimulation (Kochenderfer et al. 2009). 
Their early clinical trial protocols involved the administration of lymphodepleting chemotherapy, and the 
administration of autologous CAR-redirected T-cells which were transduced with a gammaretroviral 
vector. In the setting of B-ALL, 14 out of 20 patients with ALL developed complete remissions, 12 of 
whom became MRD negative (Lee et al. 2014). After MRD negative CR the leukaemia-free survival 
chance was 78%. All responding patients developed CRS. Using the same CAR construct in NHL is 
likewise promising, with 4 out of 7 patients with chemo-refractory diffuse large B-cell lymphoma 
attaining CR after CAR treatment, and ongoing remission in 3 (Kochenderfer et al. 2014). This is the 
first group to demonstrate CAR responses in DLBCL. 
 Multiple other groups are actively recruiting patients for CAR-CD19 trials. The exact CAR 
construct and clinical trial procedures differs with all, but it will be a fascinating area to follow in future. 
 1.5.5 Risks of chimeric antigen receptor redirected T-cells 
There are several theoretical and actual risks inherent in treatment with CAR-redirected T-cells. In 
broad terms the risks of CAR T-cell infusion on patients relates either to the tissue expression of the 
antigen of interest, so called ‘on-target, but off organ’ effects, or to infusional effects of the redirected 
cells. As our focus is CD19-redirected T-cells, and the expression of CD19 is restricted to B-cells and 
follicular dendritic cells (and no stem cell expression), the only ‘on-target’ toxicity is persistent B-cell 
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aplasia which has been discussed previously in section 1.2.3. Therefore this section will confine 
comments to the infusional toxicity of CAR T-cells. Genotoxicity risks relating to the genetic engineering 
required for T-cells to express CAR are discussed in later sections. 
 It is important to note that several patients have died, and there have been life-threatening 
toxicity events that are directly attributable to infusion of CAR T-cells. Certainly the most important 
treatment related adverse event to highlight in the trials reported so far is the issue of Cytokine Release 
Syndrome (CRS), and the related disorders Tumour Lysis Syndrome (TLS) and Macrophage Activation 
Syndrome (MAS). So far CRS has been described in all CD19-CAR trials where a second generation 
CAR or later was used, and where the CAR T-cells were administered into patients with active B-cell 
tumours. CRS develops within hours to days of CAR-T administration, and the hallmark features are a 
refractory fever and marked elevations in measurable inflammatory cytokines. Proposed criteria for 
severe CRS include the additional criteria of organ toxicity, in the form of hypotension, neurotoxicity, or 
hypoxia (Davila et al. 2014). Though the exact mechanisms of CRS remain to be elucidated, the core 
features are that CRS onset occurs as the numbers of CAR-redirected T-cells proliferate in vivo, and 
are presumably a response to the cytokine storm following CAR T-cell activation with antigen. Direct 
tumour lysis by T-cells almost certainly plays a part, and it is highly likely that the clinical CRS 
syndromes observed are a combination of true TLS with additional cytokine storm features of massive 
cytotoxic T-cell activation. The hallmark feature which has been consistently described is massive 
elevations in interleukin-6 and other cytokine blood levels (Porter et al. 2011, Grupp et al. 2013), a 
finding which is potentially targeted with the anti-IL6 receptor antibody tocilizumab. Macrophage 
activation syndrome has been additionally described with massive increases in ferritin, coagulopathy, 
hepatosplenomegaly and a morphological finding of haemophagocytosis on bone marrow biopsy. This 
has been reported separately from CRS at least in one child (Grupp et al. 2013), but it is far from clear 
whether this is a separate or additional pathology, and would be more likely to represent a spectrum of 
CAR T-cell related CRS. Neurotoxicity is a common finding in severe CRS also, and there may be 
additional direct CNS effects due to translocation of CAR T-cells into the CSF, though it is interesting to 
note that neurotoxicity is one of the serious toxicities also seen with CD19 directed BiTE therapy with 
blinatumomab (discussed in section 1.2.3) (Topp et al. 2011). CRS incidence remains unclear, as it is 
yet early days with CAR treatment, and there may be differences with the various CAR-trial designs. 
With the UPenn approach, severe CRS has been described in 64% of ALL patients, and 16% of NHL or 
CLL patients treated so far (Frey et al. 2014). The CRS may be very severe, in fact several patients 
have died with the complications of refractory CRS despite intensive treatment (Frey et al. 2014). 
Importantly, all three cases of death from refractory sCRS were associated with infection. It does 
appear that the severity of the observed CRS is proportional to the tumour cell burden at the time of 
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infusion, and conversely that the lack of CRS correlates with a lack of tumour response and T-cell 
persistence (Maus et al. 2014). Treatment of severe CRS includes the prompt initiation of 
corticosteroids, anti-IL6 receptor mAb, and intensive supportive care. Prognosis after severe CRS 
remains unclear. Whether overtreatment of CAR T-cell induced CRS could abrogate the therapeutic 
efficacy of the cells is a matter of significant concern, but most authors appear to agree that severe 
CRS should be treated promptly and maximally given the risk of death. 
 Given the concern about severe CRS several strategies are under evaluation to mitigate the 
severity. Administration of lymphodepleting chemotherapy may go some way to reduce the CRS 
severity by reducing tumour burden prior to CAR administration, as of course would CAR administration 
earlier in the disease course. Various groups are also incorporating suicide gene insertions along with 
the CARs. The concept of suicide gene is the insertion of a non-toxic gene product co-expressed in 
CAR T-cells, activation of which results in rapid T-cell clearance in the event of CAR related toxicity. 
Some of the suicide gene strategies being explored include the use of inducible Caspase 9 (iCasp9), a 
chimeric gene product which induces rapid apoptosis when exposed to an otherwise non-toxic 
dimerising agent (Hoyos et al. 2010), the use of an HSV derived protein for ganciclovir sensitivity 
(Uckert et al. 1998), or the enforced expression of a c-Myc amino acid tag or other mAb targetable 
epitopes on the T-cell surface (Kieback et al. 2008). 
 There are other infusional toxicities possible with CAR treatment. Anaphylaxis to the CAR itself 
has been described in at least one case of a patient who was treated with repeated infusions of T-cells 
transiently transfected to express CAR by mRNA (Maus et al. 2013). In this trial the T-cells were 
transfected with an anti-mesothelin CAR derived from a murine clone. The authors very clearly 
demonstrated a classical cytokine profile consistent with IgE mediated anaphylaxis in this case, and the 
finding of human anti-mouse antibodies in serum. The patient survived and convalesced well. Though 
they were unable to definitively conclude that it wasn’t some other component of their CAR 
manufacturing protocol, certainly the most likely event was a specific IgE reaction directed against the 
murine components of the CAR. Whether this is also a concern in humanised CAR constructs or 
different CAR manufacturing methods remains unclear, but anaphylaxis would appear to be possible in 
most circumstances, particularly if there was repeated exposure to CAR. Rapid death following a CAR 
targeting ERBB2 was reported in one case of a patient with metastatic colon cancer (Morgan et al. 
2010). In this case the patient received a large dose (1010) of transduced cells intravenously after 
chemotherapy, and then had a reaction within 15 minutes which led to death. This case has elements 
of both cytokine storm, and also ‘on-target off organ’ toxicity, as ERBB2 was found to be expressed at 
low levels by pulmonary epithelium. Later generation CAR trials have incorporated dose-escalation 
components, and one would hope this adverse event would not be repeated. Importantly, suicide gene 
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insertion would not help in the above scenarios (anaphylaxis or other immediate infusion reaction) as 
the toxicity develops too rapidly for there to be any benefit from CAR T-cell clearance.   
1.5.6 Redirection of different T-cell subsets using chimeric antigen receptors 
CAR-redirected T-cells have enormous potential in oncology, and there are multiple groups across the 
world with active trials recruiting at the present time, with stunning early successes. However there 
remain many unanswered questions as to the optimum CAR design and implementation strategy. Of 
the innumerable issues which remain to be investigated one of the more interesting questions is that of 
the optimum T-cell subset to be redirected. 
 Of necessity, when bulk primary human T-cells harvested from peripheral blood are transfected 
to express CAR, all the T-cell subsets represented in that sample will express CAR to the same extent. 
For tumour immunotherapy presumably the beneficial cells will be the cytotoxic T-cells which can 
engage with and lyse tumour cells expressing the CAR antigen, but of course the presence of CAR-
redirected tumour specific T-regulatory (Treg) cells could potentially antagonise CTL effects, or even 
foster tumour immune-evasion. For that matter all non T-lymphocytes present in any given sample 
would also be redirected, with unknowable consequences. Separate from the concern about 
inadvertent Treg redirection is the increasing recognition that not all lymphocytes are created equal 
when it comes to persistence and proliferative ability.  
 Various groups have investigated different T-cell subsets for redirection and have ‘placed their 
bets’ on different approaches. The early successes with CD19-redirected CAR cells from the University 
of Pennsylvania group mentioned earlier have all involved the bulk redirection of autologous PBMCs 
without any selection step. In fact those transfected cell products had a low level of CAR expression 
transfection in their original cohorts, with the first reported CLL patient being transfected with 3x108 T-
cells, of which only 5% were transduced (Porter et al. 2011). Despite the lack of a specific T-cell subset 
redirection many of their patients have shown excellent and long-lasting leukaemia responses. Other 
groups have taken different approaches. Given that large numbers of allogeneic T-cells specific for 
CMV and EBV have been administered to patients without GvHD, one of the approaches being 
explored by the Fred Hutchison Cancer Research Center (Seattle, WA) is to express CARs specifically 
within central memory virus-specific CD8+ cells by means of immunomagnetic selection prior to 
transfection, followed by streptamer selection (Terakura et al. 2011). The same group are now running 
a clinical trial incorporating these techniques (Riddell et al. 2014). Natural Killer cells (NK cells) have 
also been redirected with CAR, as they have intrinsic anti-tumour properties as outlined in prior 
sections. For example, by incorporating an NK specific activation signal into CAR design Altaver and 
colleagues were able to specifically enhance CAR-redirected NK function ex vivo, and this sort of 
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approach is generally applicable to all NK targets (Altvater et al. 2009). A research group from Ohio 
State University (Columbus, OH) have successfully redirected NK cells with a CS1-directed CAR for 
myeloma therapy with promising preclinical activity (Chu et al. 2014). An extremely promising subset of 
human memory T-cells with stem-cell like properties has been described recently by a group from the 
National Cancer Institute (NIH, Bethesda, MD) (Gattinoni et al. 2011). The in vitro proliferative 
properties of these TSCM cells when redirected by CAR were superior to any other T-cell subset, and 
thus are a promising avenue for CAR-redirection. 
 Intriguingly, CARs can also redirect T regulatory lymphocytes for the purposes of immune 
tolerance. Though a full discussion is beyond the scope of this thesis, there is an enormous potential 
for such an approach in GvHD therapy and organ transplantation in general. For example, in two 
related murine models of colitis, T-regulatory cells redirected with a CEA-specific CAR effectively 
abrogated gut inflammation regardless of the cause (Blat et al. 2014), and separate studies have 
confirmed that Tregs expressing a neuronal-directed CAR have the ability to track to the CNS and 
completely abrogate inflammation in a murine multiple sclerosis model (Fransson et al. 2012). 
1.6  Genetic engineering techniques to express chimeric antigen 
receptors 
There are various approaches to enable expression of CARs in T lymphocytes. In essence all are 
genetic engineering techniques which enforce expression of the transgenic CAR protein in T-
lymphocytes. For ongoing CAR expression by T-cells, a construct which encodes for the CAR and a 
promoter element must be permanently integrated into the genome. The options for this approach 
include viral, meaning gamma-retroviral or lentiviral approaches, and non-viral approaches, which 
incorporates the use of transposon systems such as Sleeping Beauty and piggyBac. For some 
applications, permanent genomic alteration may be unnecessary, in which case non-integrating 
methods can be employed. This section will briefly summarise these techniques. The strength and 
weaknesses of the various options are summarised in Table 1-. 
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Table 1-1: Comparison of different gene expression techniques for chimeric antigen receptors 
 Mechanism Benefits Safety Concerns Practical Issues Key references 
Non-integrating vector systems for transient gene expression 
Ad5F35 and 
AAV 
vectors 
Non-pathogenic, 
engineered virus 
vectors, non-integrating 
Wide expression in 
human tissues, 
crosses blood brain 
barrier 
Potential for replication 
competent virus, cross-
transfection with wild-type 
Hard to produce in large scale, extensive 
testing required for GMP, small payloads 
(<5Kb inserts), potentially immunogenic 
(Kotin et al. 
1990, Mezzina 
and Merten 
2011) 
Plasmid 
DNA 
Coding DNA (with 
promoter element) 
transfected into cell 
nucleus 
High expression, 
widely used. 
Inadvertent genomic 
integration 
pDNA results in cellular toxicity, 
electroporation at high voltages needed 
for nucleofection 
 
mRNA 
Electroporation of gene 
coding mRNA directly to 
cytoplasm 
Very high 
expression with low 
electroporation 
voltages, non-toxic, 
large payloads 
 
Transient expression due to degradation 
of mRNA and cell division 
(Zhao et al. 
2006) 
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Integrating vector systems for sustained gene expression 
γ-retrovirus 
vectors 
Modified from non-
human pathogenic 
retrovirus class, recent 
changes include self-
inactivating designs, 
non-replication 
competent 
High-expression, 
permanent gene 
integration 
Insertional mutagenesis, 
demonstrated 
leukaemogenesis, 
replication competent virus 
concerns 
Needs dividing cells, production requires 
packaging cell lines, extensive testing 
and regulatory hurdles 
(Rosenberg et 
al. 1990, 
Mulligan 1993, 
Hacein-Bey-
Abina et al. 
2014) 
Lentiviral 
systems 
Modified from HIV and 
SIV, 4th generation are 
self-inactivating and 
non-replication 
competent 
Transfects non-
dividing cells, highly 
efficient 
transfection, 
targetable, 
demonstrated 
safety profile 
Insertional mutagenesis, 
replication competent virus 
concerns 
Production requires packaging cell lines, 
extensive testing and regulatory hurdles 
(Dull et al. 1998, 
Zufferey et al. 
1998, Zhou et al. 
2012) 
Sleeping 
Beauty 
transposase 
Modified DNA 
transposable element 
retro-engineered from 
salmon genomes 
Efficient, payloads 
up to 12Kb 
Insertional mutagenesis, 
genomic toxicity from local-
hopping and persistent 
transposase activity 
Requires electroporation of two DNA 
plasmids, transfection efficiency reduces 
with large inserts 
(Ivics et al. 
1997, Karsi et al. 
2001) 
piggyBac Modified DNA Highly efficient, Insertional mutagenesis, Requires electroporation (Cary et al. 
Table 1-1 (cont.) 
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transposase transposable element 
from Cabbage looper 
moth 
payloads up to 
18Kb, footprint-free 
excision, self-
inactivating designs 
available, 
potentially genome 
site-specific 
insertion in future 
genomic toxicity from local-
hopping and persistent 
transposase activity (though 
recent advances remove 
this issue) 
1989, Li et al. 
2001, Manuri et 
al. 2010, 
Urschitz et al. 
2010, Yusa et al. 
2011, Li et al. 
2013) 
 
 
Table 1-1 (cont.) 
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1.6.1 Non-integrating methods for chimeric antigen receptor expression 
 Viral and non-viral non-integrating methods of transgene expression are both options for those 
situations where permanent CAR expression is not necessary or desirable. In general non-integrating 
methods have been shown to induce CAR expression for up to one week, before loss of expression 
due to vector degradation or dilution due to T-cell division. The desirability for transient CAR expression 
may include safety concerns, as CAR expression could be expected to dissipate over time after 
transfusion, and also practical concerns as the various integrating genetic engineering methods have 
limited ‘payloads’ for the exogenous genes which can be integrated, which is a lesser concern when the 
need for genomic integration is not an issue.  
 The most common viral non-integrating method to date utilises replication-defective adenovirus 
vectors and adeno-associated viral vectors (AAV). Though widely used for gene delivery in both 
proliferating and quiescent cell types, the adenovirus serotype 2 and 5 (the commonest Ad-vectors) are 
very poor at delivering transgenes to lymphocytes or any other committed haematopoietic lineage cell, 
as such cells lack the coxsackie/adenovirus receptors and αV integrins which are prerequisites for 
efficient adenoviral attachment (Wickham et al. 1993). Chimeric adenovirus vector with elements of 
serotypes 5 and 25 were therefore developed, the Ad5F35 vector, which can efficiently transfect both 
resting and activated lymphocytes (Yotnda et al. 2001, Schroers et al. 2004). The Ad5/F35 vector binds 
instead to CD46 which is ubiquitously expressed (Yotnda et al. 2001). Using such as system up to 90% 
of T-cells can be rendered positive for transgene, albeit for less than one week (Perez et al. 2008, June 
et al. 2009). Although Ad5F35 vector transgene expression does not maintain over time, it remains 
unclear whether residual viral proteins would render T-lymphocytes immunogenic and affect 
persistence (or if this would even pose a problem anyway). Like Ad-vectors, Adeno-associated viruses 
are genetically modified non-pathogenic DNA viruses which essentially stay episomal and do not 
integrate into the host genome (Mezzina and Merten 2011). Wild type AAV lays dormant until co-
infection with adeno- or other helper viruses, hence the name. Wild type AAV does have the unique 
ability to insert into the human genome at a specific site (the S1 site on chromosome 19), an ability 
which can be exploited for site-specific gene integration, but this ability has been removed in the 
recombinant AAV-vectors (Kotin et al. 1990). They have an intrinsic payload limit of ~ 5kb, smaller than 
most other non-integrating systems, but have wider host expression compared to retroviral vectors, and 
in particular AAVs have the ability to cross the blood-brain barrier, which may be important in gene 
therapy trials for neuro-degenerative diseases. 
 Non-viral, non-integrating methods exploit the ability to transduce lymphocytes with plasmid 
DNA (pDNA) or RNA. Plasmid DNA can be introduced to cell nucleus ex vivo through a variety of 
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methods including, most commonly, electroporation. Electroporation involves the application of a 
transient voltage across the lipid bilayer cell membranes which results in pore formation and resultant 
translocation of charged macromolecules into the cell interior (Neumann et al. 1982). Electroporation 
has the capacity to irreversibly harm cells when the voltages are too high, but the poration effect is fully 
reversible at lower voltages and can result in highly efficient nuclear delivery of the molecules of 
interest. pDNA gene expression is commonly employed in all aspects of genetic engineering, and forms 
an important part of retroviral and transposon based systems as well. Although plasmid DNA delivery 
by electroporation can result in highly efficient CAR expression, there is the theoretical concern about 
transient integration, and such pDNA is innately toxic to cells. Even higher transfection efficiencies 
(approaching 100%) with lower cellular toxicity and additional potential safety benefits have been 
reported when RNA is electroporated into cells instead of plasmid DNA. mRNA need only be 
electroporated to the cell cytoplasm for activity, and therefore requires much lower electroporation 
settings. For example, Zhao and colleagues reported over 90% expression and >80% cell survival for a 
variety of transgenes, including artificial TCRs, when electroporated at low voltages using mRNA (Zhao 
et al. 2006). In terms of CAR expression per se several groups have published using RNA 
electroporation with impressive results. Yoon and colleagues achieved >90% CAR expression in all T-
cell subsets with a Her-2/neu targeted CAR using mRNA electroporation, with persistence of 
expression (and cytotoxic function) out to 6 days after electroporation (Yoon et al. 2009). With mRNA 
electroporation the necessary voltages are low, and RNA-based approaches are expected to be 
innately less genotoxic when compared to DNA approaches, and are under active evaluation for clinical 
trials currently.    
1.6.2 Viral methods for gene integration 
Although there is promising gene transcription efficiency and lack of cellular toxicity seen with RNA-
electroporation in particular, it is widely assumed that in order to obtain lasting anti-tumour responses, 
permanent chromosomal integration of CAR-genes will be required. Methods with low immunogenicity 
are necessary, and for this reason the integrating viral vector systems use are the retroviral derived 
gammaretrovirus and lentiviral systems. The first human trial to use permanently gene modified cells, 
gene marked Tumour Infiltrating Lymphocytes (TILs) with a Neomycin resistance gene using a 
gammaretroviral vector derived from the Moloney murine leukemia virus (MLV) (Rosenberg et al. 1990). 
Gammaretroviruses are a class of retrovirus which are not thought to cause human disease, and which 
have been modified for cell therapy. The essential advantage of these vectors over the traditional 
adeno-associated viral vectors and others is the ability to integrate transgenes permanently into 
genomic DNA using reverse transcription and integrase (Mulligan 1993). Though specific viral receptor 
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molecules would be needed for viral integration from native MLV, this problem is largely overcome by 
pseudotyping vectors with envelope proteins from other viruses, such as the Vesicular Stomatitis Virus 
G protein, which can transduce a wide range of mammalian cell types (Hu and Pathak 2000). The 
disadvantages of gammaretroviruses are that their use is quite cumbersome due to the need for 
dividing cells, a problem which was largely overcome by the development of Lentiviral vectors (LVs) in 
the 1990s (Naldini et al. 1996, Zufferey et al. 1998). Lentiviral vectors, derived from HIV and SIV, can 
infect non-dividing cells such as neurones, and they can carry a higher payload than 
gammaretroviruses, and can furthermore be modified with safety switches to ‘self-inactivate’ after 
integration, and potentially have a safer genomic integration site profile when compared to 
gammaretroviral systems (Matrai et al. 2010). An exciting recent development in Lentiviral vector 
targeting has been developed recently by incorporating scFvs into the LV particle envelope, thus 
limiting gene transfer to the cell type of interest. The proof of principle was reported by Zhou and 
colleagues, and relied upon the genetic modification of measles virus envelope glycoproteins to 
express a CD8 directed scFv, whilst blinding the same proteins for their natural receptors (Zhou et al. 
2012). This enabled the authors to exclusively transfer their transgenes (in this case artificial TCRs) to 
CD8+ cells, with the potential to retarget any given LV vector simply by incorporating a different scFv. A 
third class of retroviral vectors is under development derived from the Human Foamy Virus, a member 
of the spumavirus retrovirus class, which has the advantage of being entirely non-pathogenic in 
primates and humans (Russell and Miller 1996, Rethwilm 2007, June et al. 2009). 
1.6.2.1 Problems with retroviral transfection systems 
There are several safety and practical concerns with retroviral vector systems for gene transduction. In 
the first therapeutic human gene trials to use gammaretrovirus vectors, 5 out of 20 children with severe 
combined immunodeficiency (SCID) of the X-linked and adenosine deamidase deficiency types 
developed T-cell ALL within 5 years of treatment (Hacein-Bey-Abina et al. 2003, Hacein-Bey-Abina et 
al. 2008, Hacein-Bey-Abina et al. 2014). In these trials the children had ex vivo transduction of 
autologous CD34+ cells with gammaretroviral vectors derived from Moloney MLV containing the 
relevant missing genes. These vectors contained duplicate enhancer sequences and have been shown 
to have preferentially inserted adjacent to proto-oncogenes LMO2 and CCND2 in patients who 
developed ALL. There were numerous additional genetic changes also found in the blast cells, but all 
derived from the gene-modified haematopoietic stem cells.  This has been widely interpreted to have 
been an insertional mutagenesis event, i.e leukaemogenesis due to genetic changes induced by vector 
gene transfer. However it remains unclear whether it was a general effect of reverse gene integration 
by retrovirus, or (more likely) factors to do with the vector design per se which led to the leukaemias. An 
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important point in this regard is that no other cancers due to the gene modified cells have been 
reported to date with any other gene therapy trial, including in CAR trials using retroviral vectors. It is 
almost certain that the duplicate enhancer sequences in their original construct, in conjunction with the 
intrinsic features of the transgene, which led to the tumours in those 5 cases. The same group have 
now redesigned their original gammaretroviral construct to become ‘self-inactivating’. Their new 
construct has the LTR U3 enhancer deleted and a human gene promoter for the IL2Rγ gene insert 
(from the EF1α gene), and no further cases of leukaemia have been reported in 9 X-linked SCID boys 
treated with this vector so far, after 12-38 months of follow-up (Hacein-Bey-Abina et al. 2014). 
Insertional mutagenesis is not only a concern with retroviral vectors, but is common to all gene transfer 
techniques which rely on random insertion sites within the genome. The other major safety concern with 
retroviral vectors is the propensity to form replication competent virus and/or combine with wild-type. 
This is more of a theoretical concern than an observed threat, but work to mitigate this risk is ongoing. 
Later generation lentiviral vectors incorporate extra safety switches to prevent this occurring, in 
particular splitting the viral envelope genes from the gag-pol and rev sequences onto different DNA 
plasmids, and incorporating a ‘self-inactivating’ deletion into one of the LTR elements which deletes the 
TATA box (Dull et al. 1998, Zufferey et al. 1998). An example of third generation Lentiviral packaging 
elements is shown in Figure 1-13. In a sense the only way to conclusively demonstrate the biosafety of 
these modifications is through long-term follow up of clinical trials, but the safety profile to date has 
been encouraging, with over 500 patient years of safety data recently reported in retroviral-modified 
CAR cells without a single vector-induced clonal event (Scholler et al. 2012). Finally, the concern about 
inadvertent germline alteration and vertical passage of transgene to downstream generations is a live 
issue, albeit more of an ethical dilemma than a safety issue. As gene therapy becomes standard across 
the world the legal and ethical framework within which it exists will need to be constantly updated. The 
issue of trans-generational gene modification has yet to be fully addressed.  
 In terms of practical concerns both gammaretroviral and (less so) lentiviral systems tend to 
suffer from transcriptional silencing over time, which presumably relates to complex host cell responses 
to viral DNA or immunogenic effects (Ellis 2005). Lentiviral and gammaretroviral vector production relies 
upon a packaging cell line, usually HEK293 cells, which for regulatory reasons are usually only 
transiently transfected with plasmids encoding for the vector subcomponents. Thus production of large 
numbers of lentiviral particles is cumbersome and difficult to scale up. The concern about viral particle 
replication competence mandates extensive and expensive testing at each step of the process of 
lentiviral gene transduction, and is a further impediment to widespread usage. 
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Figure 1-13 Third generation lentivirus vector elements. 
The packaging and envelope plasmids have been separated from the transfer plasmid, which contains 
the transgene of interest, in order to remove the possibility of replication competent lentivirus. 
Packaging cell lines are transfected with the above plasmids following which intact, replication 
incompetent, lentiviral vectors are collected for use in cell transfection. From O’Keefe,E, 
http://dx.doi.org/10.13070/mm.en.3.174, version 2013-12-17. 
 
1.6.3 Non-viral transposon based systems for gene integration 
In the section above the use and risks of gene modification using retroviral based systems was 
discussed. The practical concerns in lentiviral systems including transcriptional silencing, lack of 
scalability, and the need for extensive testing for replication competent vector is where non-viral 
transduction using transposase systems has immense potential use in future gene therapy applications.  
 Mobile genetic elements, now known as transposons, were first discovered in the maize 
genome by Nobel laureate Professor Barbara McClintock, while she was working at Cold Spring Harbor 
Laboratory in New York in the 1940s (McClintock 1950). Both Class I (RNA transposons) and class II 
(DNA transposons) have been discovered, of which the DNA transposons are the most widely used 
class in genetic engineering at present. In simple terms a DNA transposable element consists of a 
transposase enzyme flanked by Terminal Inverted Repeats (also known as Inverted Repeats, IRs). 
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Transposase then has the ability to cut and paste the transposable elements as recognised by the IRs 
into a different site in the genome. By then separating the transposase sequence from the transposon 
element (with the inverted repeats) the transposase system is quite readily adapted for gene therapy. 
An illustration of the transposon system elements and mechanism of action available in Figure 1-14.   
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Figure 1-14 Transposon/Transposase systems for gene transduction 
A: Basic elements of a class II DNA transposable element include a transposase gene flanked by 
Terminal Inverted Repeats (TIR). B: Separating the transposase element from the TIRs into separate 
expression plasmids allows genomic insertion of transgenes by cotransfecting cells with both vectors. 
The transposase enzyme remains episomal and is not incorporated, but the transposon element is cut 
and pasted into the chromosome of interest. C: Illustration of the cut and paste mechanism of action of 
DNA transposons. The excision site is repaired by host factors, and the integration is adapted to 
incorporate the transposon. Figure adapted from (Munoz-Lopez and Garcia-Perez 2010).   
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There are several transposase systems derived from eukaryotic species which have been adapted for 
gene therapy. Sleeping Beauty is a member of the Tc1/mariner class of transposons, and was the first 
such system adapted for gene therapy, having been discovered through a reverse engineering 
technique from different salmon species (Ivics et al. 1997). It is active in cells derived from species as 
diverse as protozoa through to humans and other primates, and results in stable/permanent gene 
expression after transfection. A hyperactive Sleeping Beauty transposase was developed which has 
100-fold increased activity over standard transposase (named SB100X), and this system can efficiently 
and permanently transduce human cells with up to 10Kb inserts, however transfection efficiency falls 
with larger inserts (Mates et al. 2009). Sleeping Beauty targets the TA tandem nucleotide, with non-
coding intergenic regions as the integration site preference. Other transposase systems from the same 
superfamily have been discovered as well including Frog Prince, from the Northern Leopard frog Rana 
pipiens, Minos, from Drosophilia hydei, and Himar1, isolated from the fly species Haematobia irritans 
(Munoz-Lopez and Garcia-Perez 2010). These transposases exhibit subtle differences in activity, such 
as different preferences for genomic insertion sites (E.G. Frog Prince shows preference for intronic 
insertions within genes).   
 PiggyBac is another superfamily of transposable elements in wide use for gene therapy 
applications at present. The original 2.7Kb piggyBac transposable element, including the transposase 
enzyme and the inverted repeat (IR) DNA segments flanking the transposable element, was recognised 
and isolated from Baculovirus infected cells of the cabbage looper moth Trichoplusia ni in the late 
1980s (Cary et al. 1989). Like Sleeping Beauty, piggyBac is active in a wide variety of eukaryotic cells 
including human T-cells, and several more active transposase elements have been developed (Lacoste 
et al. 2009, Yusa et al. 2011, Burnight et al. 2012). One of these more active transposases, the 
‘hyperactive 7pB’ from Doherty and colleagues developed at the Baylor College of Medicine (Houston, 
TX), has 2-3 fold higher transposase activity in vitro than both native piggyBac and SB100X, and 
without a reduction in efficiency with higher payloads (Doherty et al. 2012). The insertion target 
sequence of piggyBac is TTAA, and the TTAA rich genomic regions are therefore the insertion 
preference sites. This results in a weak tendency to insertional proximity to transcriptional elements and 
CpG islands (Galvan et al. 2009, Woodard et al. 2012). When analysed in comparison to 
gammaretroviral and lentiviral vectors piggyBac had decreased integration frequency near to known 
proto-oncogenes, which implies that the risk of insertional mutagenesis may be lower (Galvan et al. 
2009). The insert payload of piggyBac is high, with inserts of up to 12Kb reported without falls in 
efficiency, and insert sizes of up to 18Kb have been successfully and repeatedly delivered in embryonic 
stem cells (Lacoste et al. 2009). A unique feature of piggyBac is the capacity for ‘footprint-free excision’ 
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of the transposon, which has led to much interest in the use of piggyBac for ‘transgene free’ inducible 
pluripotent stem cell development, where reversible gene integration is desirable (Yusa et al. 2009). 
 As yet it is early days in the use of transposase systems for genetic engineering, and the 
optimal system is yet to be defined. PiggyBac does have some advantages over the other common 
system employed, Sleeping Beauty, with higher transfection efficiency in its hyperactive form, and a 
higher insert payload potential. In terms of CAR-transfection the ability of piggyBac to reversibly excise 
transgene is not important, and yet the other features indicate that the piggyBac 
transposase/transposon system is a highly flexible and potentially useful system for the genetic 
modification of T-cells. 
1.6.3.1 Safety of transposon systems 
The main safety concern of transposon systems is that of potential insertional mutagenesis. However, 
unlike in the gammaretroviral trials mentioned previously as yet there have been no cases of 
transposon-induced cancers in human trials, and the genome insertional preferences appear to be 
safer with piggyBac over retroviral systems (Galvan et al. 2009). But as with retroviral systems, both 
Sleeping Beauty and piggyBac have been used in vitro as mutagenic ‘cancer gene discovery tools’ 
(Collier et al. 2005, Rad et al. 2010). The research concept is that transposons are developed to either 
induce loss or gain of function of nearby genes, then transferred to mouse models which are innately 
predisposed to cancer (such as Arf-/- which are mice deficient in p53 and p19) and observed for tumour 
development. Whether this would ever translate to actual insertional mutagenesis in primary human 
lymphocytes is unclear, but the possibility could never be ruled out completely. Given this concern, 
efforts to improve the safety of the piggyBac system are underway by several groups. PiggyBac safety 
would be markedly improved by the ability to guide integration sites towards ‘safe-harbour’ sites within 
the genome. The most likely mechanism to achieve this would be to fuse DNA binding domains, such 
as Zinc finger proteins, to piggyBac transposase. So far several groups have shown that Zinc finger 
fusion to transposase is possible, and that the transposase retains activity when so fused, but the goal 
of site-specific gene integration has not yet been realised (Kettlun et al. 2011, Li et al. 2013). A related 
concern about piggyBac induced genomic toxicity and insertional mutagenesis is that of ‘local hopping’ 
and reintegration of the transposon element after initial gene transfer due to ongoing expression of 
piggyBac transposase after transfection. Reintegration of the piggyBac transposon cassette occurs in 
only half of the excision events after catalysis by the transposase, and is very likely subject to multiple 
rounds of excision and integration (Wang et al. 2008, Li et al. 2013). This may be partly overcome by 
using drug-inducible systems, but another approach is to use a self-inactivating design similar to that 
employed in lentiviral vectors. By incorporating both transposase and transposons into a single vector, 
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and embedding the 3’ inverted repeat in the transposase enzyme, Urschitz and colleagues were able to 
develop a single-plasmid piggyBac system in which the transposase becomes inactive after 
transposition, even if the post-transpositional vector backbone is inadvertently incorporated to the host 
genome (Urschitz et al. 2010). These strategies to reduce transposon related genotoxicity should 
greatly add to the perceived safety of non-viral gene modification, are not amenable to adaption for use 
in lentiviral systems. If the promise of helper- plasmid independent, transposase inactivating piggyBac 
vectors which can be targeted to genomic safe-harbours can be realised, then transposon systems will 
have an enduring safety benefit over retroviral integration systems. 
 The other main advantage transposon systems have over viral DNA integration systems is that 
of scalability. The lack of a need for gene modified packaging cells and viral-vector particle harvesting 
removes several cumbersome steps in comparison to retroviral vectors. The supply of GMP grade 
helper-donor transposon plasmids for cell transfection is effectively limitless when bacterial expansion 
methods are employed. Unlike the retroviral systems there is no chance of inadvertent replication-
competent vector development, nor is there any danger of wild-type combination in host genomes. As a 
result the testing requirements in human trials are less than that needed in virus-vector trials. The main 
dilemma for large-scale incorporation of transposon mediated gene therapeutics is the delivery method 
employed for cell transfection. Already GMP compliant high volume electroporation systems have been 
developed and are entering early phase CAR-trials currently (Li et al. 2010, Li et al. 2013).        
1.7  Overview of the Cell Therapy program at the Westmead 
Millennium Institute 
The Westmead Millennium Institute, affiliated with the University of Sydney, is located on the 
Westmead Hospital health campus in western Sydney (NSW, Australia). As Westmead hospital has 
one of the most active and well established allogeneic haematopoietic transplant services in Australia, 
the focus of the affiliated cell therapies group within WMI has been towards restoration of normal 
immunity post allogeneic transplantation. Under the directorship of Professor David Gottlieb, the WMI 
cell therapy group developed and conducted several innovative clinical trials in immunotherapy for 
prophylaxis against Cytomegalovirus infections following transplant (Foster et al. 2002, Foster et al. 
2004, Micklethwaite et al. 2007, Micklethwaite et al. 2008, Blyth et al. 2013). The strategy involves the 
generation of CMV-specific T-cell products ex vivo, manufactured from CMV-seropositive donors for 
patients undergoing allogeneic HSCT, which are then reinfused to patients prophylactically. Importantly, 
no cases of GvHD were attributable to the cell products infused. The safety and early success of this 
work in CMV has been used as a backbone for the development of several other cell therapy products 
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against transplant pathogens. These include VZV specific T-cells (Blyth et al. 2012), BK virus specific 
T-cells (Blyth et al. 2011), third party EBV-specific T-cells to prevent or treat EBV-related PTLD, and 
multi-fungus specific CTLs (Gaundar et al. 2012). 
 The current research priorities of the group include the development of new pathogen-specific 
T-cell cultures where there is an unmet clinical need, such as hepatitis B virus and Herpes Simplex, as 
well as combining the various specific T-cell products listed above into a ‘multi-pathogen’ virus program 
after allograft. As well as T-cell products for use in prophylactic infusions there has been recent interest 
in the development of cell products for therapeutic intent. This includes a third-party donor virus specific 
cell bank, made from consenting donors from whom excess pathogen-specific products are stored, for 
use in cases of refractory viral infection or virus-related PTLD.  
 The clinical and research expertise of the WMI Cell Therapy group provides an excellent 
opportunity for incorporation of CAR-treatment post transplantation. CAR-redirection of autologous T-
cells is highly promising, as mentioned previously. The ability to incorporate a CD19-CAR into a 
pathogen-specific T-cell culture derived from healthy donors would be a highly attractive goal as, if 
persistent, such redirected T-cells would treat or prevent CD19+ malignancies as well as preventing 
viral reactivations following allograft. In combination with allogeneic HCT such a cell product would link 
the nascent fields of ex vivo immune reconstitution and cellular-gene therapy, and potentially lead to 
cures from otherwise terminal malignancies or infections. Therefore, we undertook an assessment of 
the ability of a non-viral gene integration system, piggyBac transposase/transposon, to express a 
CD19-directed CAR in the T-cells of healthy donors in both rested peripheral blood mononuclear cells 
(PBMC) and CMV-specific T-cells generated ex vivo. 
1.8  Hypotheses and goals of the research 
The first step towards clinical trial development of CAR-integrated CTL infusions is the optimisation of 
CAR expression, enrichment, and expansion in primary cells in an ex vivo setting. Therefore prior to 
assessing CAR efficacy and safety in animal models or early phase human trials we need to 
demonstrate that enforcing and maintaining CAR expression in human T cells using the piggyBac 
Transposase/Transposon gene delivery system is reliable, reproducible and practical.  
The novelty of this approach lies in the introduction of a non-viral gene-modification step to the 
Westmead virus-specific cell therapy setting, and in the introduction of CD19.CAR work to Australia 
more generally. Also, although groups in Texas have already reported the genetic modification of T-
cells to express CAR with piggyBac, they have not done so with the Neon transfection system, which is 
highly modifiable with respect to different transfection settings, nor has this been performed with our 
specific vectors.   
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 The piggyBac system requires several elements for gene integration, all of which are variables 
potentially in need of optimisation with respect to CAR expression and cell survival. Firstly the 
transgene of interest, which in our case is the CAR.CD19-28ζ, must be subcloned into the transposon 
cassette and flanked by the piggyBac specific Inverted Repeats (IRs) in order to enable transgene 
integration. The choice of promoter is another variable. The two plasmids thus generated (the piggyBac 
plasmid carrying the transposase gene and the transposon plasmid carrying the CAR.CD19-28ζ) must 
then enter the nucleus of the cell of interest in order for gene insertion (or transfection) to take place. In 
our case we chose an electroporation platform (the Neon® transfection system (Invitrogen, Carlsbad, 
CA)) for transfection. The main variables to be assessed were the optimal voltage, pulse number, and 
pulse width to be used during electroporation. Readouts included T cell survival, growth and 
CAR.CD19-28ζ expression. In addition, as there are several piggyBac products available for 
transfection, we tested two different piggyBac transposases for transfection efficiency. 
 Once transfection with the CAR.CD19-28ζ transgene has taken place, the next steps relate to 
the optimisation of parameters to do with enrichment (increasing the numbers of transfected cells within 
each culture) and expansion (increasing the total numbers of cells in culture) of transfected cells, with 
the ultimate goal of maximising clinically meaningful numbers of CAR.CD19-28ζ transfected T cells 
(CAR T-cells) for use in animal studies or early phase human trials. The main variables to be optimised 
in this regard include the cell concentrations in culture, the type and concentrations of cytokines added 
to the culture medium, to enhance either antigen-specific or homeostatic proliferation, and the addition 
of stimulator or feeder cells to the culture in various ratios.  
 In addition, as unselected allogeneic PBMC carry a risk of GvHD similar to that seen in 
unselected DLI, we also wished to explore the expression of CAR.CD19-28ζ in both primary donor 
PBMCs and CMV-specific T-cell cultures. The rationale is that CMV-specific T-cells have a proven 
safety record with no excess risk of GvHD, and in addition the dual specificity for virus and CD19 could 
theoretically enhance persistence of transfected T-cells after infusion. The ultimate aim is integration of 
this work into the existing cell therapy program at the Cell Therapies Unit in the Westmead Millennium 
Institute as part of a clinical trial.  
 
1.8.1 Hypotheses 
 Transfection efficiency of CAR.CD19-28ζ in primary human PBMC using the piggyBac 
transposon system changes with different electroporation settings (voltage, pulse width, and 
number of pulses). 
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 Expansion of CAR.CD19-28ζ modified PBMC in tissue culture conditions will improve with the 
addition of growth cytokines (IL2, IL7 or IL15) and the use of stimulator cells which expr CD19 
antigen, compared to culturing without those additions. 
 CMV-specific CTL cultures may be transfected with CAR.CD19-28ζ using the piggyBac 
transposon system via electroporation.  
1.8.2 Statement of aims 
 
1. Optimise the electroporation settings for transfection of primary PBMCs from healthy donors 
with CAR.CD19-28ζ using the piggyBac transposase/transposon system, with respect to both 
CAR expression in CD3+ cells and cell recovery 24 hours after transfection, using the Neon® 
transfection system. The main parameter for optimisation is the Neon® transfection system 
electroporation voltage settings, with additional parameters including choice of standard 
piggyBac transposase (pCMV-PB) versus ‘super piggyBac transposase’ (superPBase), relative 
concentrations of transposase and transposon plasmids for electroporation, and concentration 
of PBMCs in electroporation buffer. 
2. Optimise the parameters for CD3+ CAR expression and cell expansion following transfections. 
Parameters for optimisation include: optimal cytokine mixture (IL2, IL7 and IL15), choice of 
stimulator cell, and ratio of Responders to Stimulators (R:S ratio). 
3. Development of a reliable and reproducible method for developing CAR expressing CD3+ 
PBMCs in suitable numbers for use in later experiments and in vivo trials. 
4. Replicate results of PBMC CAR expression optimisation program with CMV specific CTLs. 
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2.1 Materials 
2.1.1 Plasmids 
Four main DNA plasmid vectors were used in the experiments described (see Figure 2-15). pCMV-
piggyBac (denoted pCMV-PB in text) carries the original piggyBac transposase driven from the CMV 
immediate early (CMV IE) promoter. It is the helper plasmid for transgene integration. The super 
piggyBac transposase plasmid (denoted superPBase in text) carries a hyperactive piggyBac 
transposase enzyme with a POLr2A gene promoter. piggyBac transposon plasmids were used which 
carry the piggyBac specific inverted terminal repeat elements flanking the transgenes. One is pIRII-
eGFP carrying the CMV IE promoter, a multiple cloning site, IRES element and eGFP sequence (total 
insert size 3.6kb). The second is the transposon carrying the CAR.CD19-28ζ insert, pIRII-CMV-
CAR.CD19-28ζ (denoted PB-CAR in text, insert size 4.5kb). The CAR is a second generation construct 
originally described by Loksog et al from the Center for Cell and Gene Therapy (Baylor College of 
Medicine, Houston, TX),  which includes an scFv derived from the parent αCD19 monoclonal antibody 
FMC63 (Nicholson et al. 1997), in frame with an IgG1 hinge and carbohydrate spacer, the CD28 
derived transmembrane and intracytoplasmic signalling domains, and terminating in the CD3ζ chain 
(Loskog et al. 2006). A third commercially available piggyBac GFP expression vector, denoted PB-EF1-
GFP, which uses the human promoter from the elongation factor 1α gene, was used in some 
experiments. All plasmids are circular double stranded DNA plasmids with an ampicillin resistance 
cassette for plasmid expansion in bacteria. 
 SuperPBase and PB-EF1-GFP were purchased from System Biosciences (Mountain View, 
CA), the remainder were kindly provided by Doctors Malcolm Brenner, Gianpietro Dotti and Matthew 
Wilson, The Center for Cell and Gene Therapy (Baylor College of Medicine, Houston, TX). As a positive 
control for eGFP experiments the pEGFP-N1 plasmid was used (Clontech, Palo Alto, CA). 
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Figure 2-15 piggyBac transposase and transposon vectors 
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Two piggyBac transposase enzymes were utilised, the pCMV-PB (figure A) and superPBase (figure B). 
The two transposon vectors (figures C & D) carry either eGFP or the CAR flanked by the piggyBac 
inverted repeat elements for gene integration. The size of the whole plasmid or the transposon element 
is indicated. CMV, cytomegalovirus immediate early promoter; POLr2A, the POLR2A gene promoter; 
IR, inverted terminal repeat; MCS, multiple cloning site; IRES, internal ribosomal entry site; eGFP, 
enhanced green fluorescent protein; pA, polyadenylation signal; CAR, chimeric antigen receptor; scFv, 
single chain variable fragment, in this case specific for CD19. Figure adapted from (Nakazawa et al. 
2009) 
 
2.1.2 DNA purification reagents 
E.coli JM109 competent cells were purchased from Promega (Madison, WI).Buffer TE, SOC medium, 
TBE buffer and selective LB media were produced in house by the Westmead Millennium Institute 
(WMI).Ampicillin was purchased from Sigma Life Science (St Louis, MO). Endotoxin free maxi plasmid 
purification kits were purchased from Qiagen (Venlo, Limburg, Netherlands). The restriction 
endonuclease EcoRI was purchased from Promega (Madison, WI), and BamHI, and XbaI were 
purchased from New England Biolabs (Ipswich, MA).   
2.1.3 Electroporation reagents 
All electroporation was performed using the Neon® transfection system and associated reagents (Life 
Technologies (formerly Invitrogen), Carlsbad, CA). Buffer T and the 100µl pipette tips were used for all 
electroporation procedures according to the manufacturer’s instructions. 
2.1.4 Tissue Culture reagents 
Trypan blue 0.4% solution was purchased from Sigma Life Science (St Louis, MO). Ficoll-hypaque was 
purchased from GE Healthcare (Uppsala, Sweden). 'Cryosure’ DMSO was purchased from Wak-
Chemie Medical GmbH (Steinbach, Germany). AIM V serum free culture medium was purchased from 
Life technologies (Grand Island, NY). Fetal calf serum (FCS) was purchased from JRH Biosciences 
(Lenexa, KA). Calcium and magnesium free Dulbecco’s Phosphate-Buffered Saline (DPBS) and RPMI-
1640 media were purchased from Lonza Biowhittaker (Walkersville, MD). The T-cell media (TCM) 
described in the text refers to AIM-V +10%FCS. 
The research grade recombinant human cytokines IL2, IL4, IL7, and IL15 were purchased from 
Millipore (Billerica, MA). 
The TPRVTGGGAM-nonapeptide (designated TPR- or TPR-peptide in text) used for CMV-specific CTL 
generation was purchased from Mimotopes (Clayton, VIC, Australia). 
Perspex Culture flasks and plates were purchased from Becton Dickson Labware (Franklin Lakes, NJ).  
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The G-REX culture flasks were provided by Wilson-Wolf Manufacturing Corporation (New Brighton, 
MN). 
2.1.5 Flow Cytometry reagents 
Monoclonal antibodies were used to characterise CMV-specific CTL and CAR-transfected PBMC 
cultures. CD3-PECy7, CD8-PerCP and 7-Amino-Actinomycin D (7AAD) were purchased from BD 
Biosciences (San Jose, CA). DyLight649-conjugated goat anti-human IgG (Heavy and Light chain) 
antibody (product number 109-496-088) and goat-IgG isotype control antibody (product number 005-
490-003) for CAR detection on T-cells were purchased from Jackson ImmunoResearch (West Grove, 
PA). These antibodies are polyclonal, affinity-purified antibodies, and the staining method was direct 
(i.e. no secondary detection antibodies were employed). MHC class I HLA:B*07 tetramer complexed to 
TPRVTGGGAM and conjugated to the fluorochrome PE was purchased from Beckman-Coulter 
(Fullerton, CA). 
2.2 Donors 
All PBMC were manufactured from venesection products taken from otherwise healthy patients 
undergoing therapeutic venesection for genetic HFE-haemochromatosis at the Westmead hospital 
venesection clinic. Donors were initially approached for consent by their treating Haematologist at the 
time of referral for venesection. Donors provided written informed consent for release of the cells for 
laboratory research under the Westmead Hospital Human Research Ethics Committee (HREC) 
approved consent form for general laboratory research. Whole blood 450ml venesection was performed 
under standard aseptic technique and transferred to the WMI Cell therapies lab for processing. All 
donor samples were anonymised with a four letter name code and the date of venesection. HLA-typing 
was performed by the Australian Red Cross Blood Service (ARCBS, Alexandria, NSW) and CMV-
serostatus was determined by ELISA for IgG and IgM late CMV antigens by the Institute for Clinical 
Pathology and Medical Research (ICPMR, Westmead, NSW). Data files linking the sample codes to 
patient’s hospital Medical Record Number (MRN) were stored in a password protected environment in a 
locked office within the WMI building, which in turn is a security guarded facility with authorised access 
by ID badge only. These data were held completely separately from the data file with HLA-typing and 
viral serostatus, which was also password protected in a locked office. 
   
 
64 
 
Chapter 2 – Materials and Methods 
 
2.3 Plasmid DNA Isolation, Expansion, and Purification 
JM109 competent cells were transformed with Plasmid DNA (pDNA) according to a standard protocol. 
In brief- 100µl JM109 cells were removed from -70°C freezer and thawed on ice for 5 minutes. Chilled 
pipette tips were used to add 5µl of Buffer TE with pDNA which was mixed by flicking each tube. The 
JM109 cells were rested on ice for 10 minutes, then heat shocked for precisely 45 seconds in a 42°C 
water bath, then placed back on ice for 2 minutes. 900 µl of 4°C SOC medium was added and the cells 
were incubated for 1 hour at 37°C in a shaker. Thereafter, cells were plated onto ampicillin selective 
LB/agar plates in two concentrations (one had 100 µl of JM109 cells and the other 900 µl) using sterile 
glass pipette tips, then incubated inverted overnight. 
 Single colonies were picked from the agar plate and used to inoculate starter cultures with 3mls 
of LB media plus ampicillin 1:1000 dilution. Starter cultures were incubated for 8 hours at 37°C with 
vigorous shaking at 300rpm. Maxi cultures were prepared by inoculating 400ml ampicillin selective LB 
media in a conical flask with the starter culture and incubating for 12-16 hours overnight in the shaker at 
300rpm. Plasmid DNA was isolated from the maxi-preps using the Qiagen endofree Maxi kit as per the 
manufacturer’s directions, as published in the Qiagen EndoFree Plasmid Purification Handbook 
(http://www.qiagen.com/au/resources, most recently accessed 16/11/2014). The kit uses an alkaline 
lysis step to dissolve bacterial membranes, a binding step of pDNA to resin, removal of contaminating 
RNA, proteins and other impurities in a salt-wash step, pDNA elution and then precipitation and 
desalting by isopropanol precipitation. DNA purity and concentration was determined by 
spectrophotometry using the Warburg-Christian method. Plasmid DNA was stored in 250 µl of either 
sterile water or Buffer TE at -20°C. 
 
Restriction endonuclease (RE) digestion analysis was used to confirm plasmid DNA content. 0.7% 
agarose gels were made from 0.7% volume agarose mixed with 1 volume Tris Borate EDTA (TBE) 
which was heated and poured into moulds. A 1kb step ladder control was run with each digest. The 
expected results from digests are as follows; pCMV-piggyBac: Xba1 – 2 fragments of 2130bp and 
3382bp; superPBase: Xba1 – 2 fragments of 3178bp and 5353bp; pIRII-eGFP: BamHI – 3 fragments of 
47bp, 1808bp, and 3738bp; pCMV-CAR: Xba1 – 2 fragments of 2047bp and 4391bp. EcoRI was used 
to linearize each plasmid (as there is only one EcoRI digestion site for each plasmid) prior to agarose 
gel electrophoresis for controls.  
 
 
65 
 
Chapter 2 – Materials and Methods 
 
2.4 Tissue Culture and Electroporation 
Unless stated differently in the text, all cell incubations for tissue culture occurred in humidified 
incubators at 37°C with 5%CO2, in a PC2 certified tissue culture laboratory. 
2.4.1 Isolation and storage of Peripheral Blood Mononuclear Cells 
PBMC were isolated from whole blood or buffy coats using Ficoll gradient centrifugation. 10ml of blood 
was suspended to 40ml in DPBS and underlayed with 10ml Ficoll. After centrifugation at 650g for 20 
minutes the buffy coat was harvested, washed twice in DPBS, and then centrifuged at 450g for 10 
minutes. The resultant PBMC fraction was resuspended in the relevant medium for cryopreservation or 
culture as necessary. 
For cryopreservation, cells were suspended in freezing mixture, which consisted of 2 parts DPBS, 1 
part DMSO and 2 parts FCS. Cells were suspended in this mixture in cryovials and placed directly into -
70°C freezers. 
  
2.4.2 Generation of Cytomegalovirus specific T-cells 
CMV-specific CTLs were generated using TPR-peptide, which is an HLA:B*07 immunodominant 
epitope for CMV pp65 antigen, in a method adapted from Foster et al (Foster et al. 2004). Fresh or 
thawed PBMC from a CMV seropositive, HLA:B*07 donor were suspended to 4x106/ml in TCM and 
incubated for 2 hours. The non-adherent fraction was removed and resuspended to 2x106/ml in TCM, 
and the adherent fraction (monocytes) were then pulsed with 10ug/ml TPR-peptide. After 2 hours the 
pulsed monocytes were harvested using a cell scraper, resuspended in TCM to 1x105/ml, and irradiated 
to 30Gy. The pulsed, irradiated monocytes were added to the non-adherent PBMC fraction in a 
Responder:Stimulator ratio of 20:1, and the cultures were then incubated at 1x106/ml, 1ml per each well 
of a 24-well Perspex tissue culture plate. TCM was replenished every 2-3 days, and a second 
stimulation of monocytes was undertaken on day 8 from cryopreserved PBMC using the same process. 
IL2 was added 20U/ml from day 8, and the dose of IL2 was increased to 50U/ml from day 15. Cells 
were harvested for transfection or cryopreservation from day 21. 
In later experiments the adherence isolation of monocytes was replaced by simply adding TPR peptide 
to the PBMC in suspension from day 1, and restimulated with TPR again on day 8. 
2.4.3 Cell Line cultures 
Cells from the pre-B ALL cell line NALM-6 (DSMZ catalog number ACC 128) were thawed and washed 
twice in DPBS, then cultured in Perspex tissue culture flasks 1x106/ml in RPMI 1640 medium 
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supplemented with 10% FCS. Culture medium was replaced every 2-3 days, and the cultures were split 
and diluted back to 1x106/ml weekly or as necessary.  
2.4.4 Electroporation 
Electroporation with the Neon transfection system proceeded according to the manufacturer’s 
instructions. As our cells were primary blood suspension cells (PBMC or CMV-CTL) we used 
resuspension Buffer T for all electroporations. ‘Buffer T’ is the proprietary resuspension buffer supplied 
in the Neon transfection kit for use with suspension cells, as opposed to ‘Buffer R’ used for adherent 
cell types. For preparation, the cells were cultured for 24 hours in TCM with IL4 (1000U/ml) and IL7 
(10ng/ml). A 24-well culture plate was preincubated with 0.5ml TCM for 2 hours prior to transfection. 
The cells for transfection were washed in DPBS (Ca++ and Mg++ free) then resuspended in Buffer T to 
2x107/ml. A template free control (no template control, NTC) was always electroporated at this point, 
then thawed plasmid DNA was added to the Buffer T suspension at a concentration of 5µg/100µl for 
each vector, taking care not to add more than 10% of the total Buffer T suspension volume. The cells 
were electroporated in the 100µl Neon electroporation pipette tips at varying voltage, pulse width and 
number of pulses and the transfected cells were then added to the preincubated culture plate and 
incubated overnight. Transfected cells were then counted and analysed by flow cytometry, or 
resuspended for further expansion 24 hours after transfection.  
For some experiments the pEGFP-N1 plasmid was used as a positive GFP control using PBMC with 
identical electroporation preparation and plasmid concentration as above. 
2.4.5 Expansion of Chimeric Antigen Receptor transfected T-cells 
For expansion of CAR-redirected T-cells, PBMC were harvested 24 hours after transfection and 
resuspended to 1x106/ml viable cells in TCM, then plated 1ml each well in a 24-well culture plate. 
CD19+ stimulator (or feeder) cells, in the form of NALM-6 or autologous PBMC irradiated to 45Gy, were 
added to each well at various ratios. IL2 (50U/ml), IL7 or IL15 (both 10ng/ml) were added in various 
combinations. Half-culture media and cytokine exchanges were performed every 2-3 days or with 
change in medium colour and the cells were harvested for analysis or further expansion on day 8.  
2.5 Analytical Methods 
2.5.1 Cell enumeration and viability assessment 
Viable cells were enumerated by trypan blue exclusion using a standard haemocytometer. 10µl of cell 
suspension was combined with 10µl of trypan blue mixed and allowed to fill the haemocytometer 
chamber by capillary action. Viable cells were identified as clear cells (in contrast to non-viable cells 
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which appear blue due to staining with Trypan blue) and counted over 1mm2 (0.1µl). The viable cell 
concentration is given by the formula:  
Cells/ml = (clear cell count) X 2 X 10000 
Where 2 = the dilution factor and 10000 = the factor required to increase the volume from 0.1ul to 1 mL 
Unless stated specifically all cell counts and concentrations for experiments refer to the viable cell 
counts. 
2.5.2 Flow cytometry 
Cells were harvested and washed in DPBS then resuspended to 1x106/ml in DPBS. 2x105 cells were 
added to each FACS tube and then diluted further to 200µl. To each tube the fluorochrome conjugated 
antibodies were added: 5µl of working dilution in each case. Anti-CAR and isotype control antibodies 
(see section 2.1.5) were diluted to the same concentration. Cells were incubated for 10 minutes in the 
dark at room temperature, washed in DPBS and the supernatant discarded, then resuspended in 200µl 
DPBS for FACS analysis. Prior to FACS analysis 5µl 7AAD was added to each tube. FACS was 
performed using a BD FACSCanto II cell analyser (BD Biosciences, San Jose, CA).  
 The gating strategy is illustrated in Figure 2-16. Viable T-cells were identified via sequential 
gating through doublet exclusion, lymphocyte gating, exclusion of 7AAD positive cells, and CD3 
positivity. CAR and/or tetramer percentages were then identified as a percentage of the parent 
population (viable T-cells). Gating for CAR expression was set using the isotype control antibody. 
FACS data was analysed using FlowJo software version 7.6.4 (Treestar, Ashland, OR). 
2.5.3 Statistical Methods 
Data was analysed and graphed using Microsoft Excel 2010 and Graphpad Prism 6 for Windows 
version 6.05 (GraphPad Software, San Diego, CA). Where relevant statistical analysis for differences 
within groups was performed using one way analysis of variance (ANOVA) with repeated measures, or 
student’s T-test if there were only two conditions. 
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Figure 2-16 Gating strategy for CAR and tetramer analysis 
CAR+ and Tetramer+ T cells were identified by gating on viable (7AAD negative) T cells. The gate for 
CAR positivity was defined using an isotype control (for the anti-CAR antibody). 7AAD is actively 
excluded by viable cells. Tetramer stains with an HLA:B*07 multimer complexed to the TPR-peptide 
and implies CMV specificity. 7AAD, 7-Amino-Actinomycin D; CAR, chimeric antigen receptor; CMV, 
cytomegalovirus. 
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Chapter 3 – Electroporation of peripheral blood 
mononuclear cells 
The first priority was to examine the initial parameters around electroporation settings with respect to 
CAR expression in T-cells, and viable cell recovery after electroporation. The rationale was to attempt 
to identify a reliable and reproducible method on which to base later experiments, with the goal being to 
maximise the number of CAR-modified T-cells one day following transfection. 
3.1 Methods 
In order to optimise CAR expression, PBMCs from healthy donors were isolated from fresh venesection 
units or were taken from samples previously cryopreserved in freezing-mix at -80ºC. Donors were 
predominantly healthy patients undergoing regular venesection for hereditary haemochromatosis at the 
Westmead Venesection Clinic, and had all provided HREC approved written consent for use of their 
venesection blood in laboratory experiments. As a starting point we followed the method laid out by 
Nakazawa et al  (Nakazawa et al. 2011) and the Neon® transfection system instructions for transfecting 
primary PBMCs as per the product manual. The Nakazawa method includes the culturing of PBMC 
overnight with IL7 prior to transfection, and culturing in TCM after transfection in the presence of both 
IL4 and IL7. The rationale for these cytokines is that they are homeostatic T-cell cytokines which are 
important for T-cell survival and proliferation (Tan et al. 2001, Bradley et al. 2005), and thus were 
thought to enhance PBMC recovery prior to transfection and afterwards. A brief synopsis of the method 
is as follows: PBMCs were incubated overnight at 37ºC and 5% CO2 in TCM with IL7 (10ng/ml) in a 12-
well Perspex Tissue Culture plate at a concentration of 1x106/ml. 2 hours prior to electroporation a 12 
well culture plate was preincubated with 1ml of TCM and cytokines (IL4 and IL7, both 10ng/ml). The 
rested PBMCs were resuspended and counted, then suspended in Buffer T to a concentration of 
2x107/ml. Purified transposase and transposon plasmids were added at a concentration of 5µg/ml 
each, to a combined maximum volume of 10% of the electroporation buffer solution. Electroporation 
proceeded using the 100µl Neon® electroporation pipette tips, hence 2x106 PBMCs were 
electroporated each time. When sparking occurred, the cells were discarded. A maximum of 2 
electroporations per tip was recommended before using a new pipette tip. Electroporation setting 
variables included the voltage (up to 2400V), the number of pulses (1 or 2 only), and the pulse width 
(up to 20ms). The highest single pulse available is 2400V for 20ms. Electroporated cells were cultured 
overnight in the pre-incubated 12-well plate in 2ml of TCM at 1x106/ml with IL4 and IL7. Twenty four 
hours after electroporation the cells were resuspended and counted via trypan blue exclusion, and 
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harvested for flow cytometric analysis. All sets of experiments included a ‘no template control’ (NTC) 
(cells electroporated without the addition of plasmid) and a non-electroporated control (cells suspended 
in Buffer T with vector pDNA added but not electroporated). 
 In all later experiments the procedure was slightly altered as follows: the addition of cytokines 
to the PBMC cultures was removed, so PBMCs were cultured in TCM without IL4 or IL7 cytokines, 
either before or after electroporation; the concentration of PBMC in buffer T was increased to 4x107/ml 
without adverse event (see Figure 3-20); Neon tips were reused up to 10 times before discarding 
unless sparking occurred; after electroporation, cells were cultured in 24-well plates in 2ml of TCM 
(concentration 2x106/ml). 
 Flow cytometry was performed as outlined in chapter 2. In brief, cells were washed in DPBS, 
then 2x105 cells added to each FACS tube. 5µl of each antibody was added and incubated for 10 
minutes. Thereafter cells were washed and resuspended in 200µl DPBS for flow cytometry. Formalin 
fixation was not done as a viability assessment with 7AAD was necessary as part of each set of results. 
7AAD was added after the final resuspension, at least 10 minutes prior to analysis. Reagents for 
analysis included 7AAD for cell viability, antiCD3-PC7, anti-IgG-APC or isotype control (to detect CAR), 
and CMV-specific tetramer fluorochromes. For GFP positive controls PBMC were electroporated using 
the pEGFP-N1 plasmid with identical electroporation settings. Cells were analysed on the BD FACS-
Canto II cell analyser, and FACS analysis was performed using FlowJo software version 7.6.4 (FlowJo 
LLC, Ashland, OR). An example of the gating strategy is given in chapter 2 (Figure 2-16): in brief 
doublets were excluded, viable CD3+ cells were then gated sequentially via 7AAD exclusion and CD3 
expression. CAR positivity was defined as the percentage of viable CD3+ cells expressing CAR. The 
limit of positivity was set using goat IgG isotype control antibody, such that there were <1% non-specific 
events in the gate, with the same gate then used across all conditions for comparison. An absolute 
number of CAR positive cells could be calculated as the viable CD3+ CAR+ population as a percentage 
of total events (CAR%total) multiplied by the number of viable cells recovered. 
 Cell recovery for day 1 is defined as the absolute viable cell number detected by trypan blue 
exclusion 24 hours after transfection divided by the number transfected, and expressed as a 
percentage. For example if 2x106 PBMCs were transfected and only 1x106 viable cells were recovered 
24 hours later, the cell recovery is 50%.  
3.2 Cell recovery 
The cell recovery results for PBMCs transfected with CAR are summarised in Figure 3-17. The two 
control conditions demonstrated similar recovery: non-electroporated control averaging 63%+/-33%; 
NTC (electroporated at 2400V/20ms/1pulse) averaging 67%+/-23%. Lower recoveries were seen when 
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PBMCs were electroporated along with DNA when compared to the NTC, irrespective of transfection 
voltage (P value <0.05 for all comparisons except 2150V, one way ANOVA).  There was no finding of a 
trend towards lower recoveries with higher electroporation voltages (P=0.13, one way ANOVA). At the 
highest electroporation setting tested (2400V/20ms/1 pulse) the average recovery was 31%+/-12%. 
Attempts at using double pulses were abandoned due to excessive sparking – the maximum setting for 
2 pulses with the Neon® system is 2350V/15ms. The addition of IL4 and IL7 to the TCM in the first 24 
hours after electroporation is associated with a minor, non-significant improvement in recovery, as seen 
in Figure 3-17.    
 
 
 
 
 
Figure 3-17 No difference in PBMC recovery at higher voltages 24 hours following 
electroporation 
Average percentage cell recoveries +/- 1 standard deviation are shown. The Y-axis represents the 
average recovery of viable cells for each condition when compared to the original number of PBMCs 
electroporated. Each electroporation condition is listed as the voltage, each given with a single 
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electroporation pulse of 20ms. Each condition had at least 3 replicates (range 3 to 5) with different 
donor PBMCs except for 2400V with IL4 & IL7 which had 2. Cells were rested in TCM with IL7 before 
electroporation overnight, and after electroporation in TCM without supplemental cytokines, except for 
the ‘2400V with IL4 & IL7’ which had these cytokines added after electroporation. CAR, Chimeric 
Antigen Receptor; IL, interleukin; PBMC, peripheral blood mononuclear cell; TCM, T cell media. 
 
 
3.3 Chimeric antigen receptor expression 
CAR expression in PBMCs is summarised in Figure 3-18. There is a clear trend towards increasing 
CAR expression in viable CD3+ cells with increasing electroporation voltages (P<0.0001 for linear 
trend). However at higher electroporation voltages there are wide confidence intervals, and more 
replicates would be needed to show a statistically significant difference between 2350V and 2400V, for 
example. All settings lower than 2300V returned CAR expression below 10%, whereas the highest 
setting (2400V/20ms/1 pulse) had an average CAR expression of 26%+/-12. The two control 
conditions, non-electroporated and No Template Control, returned <0.5% expression. Single donor 
experiments with double pulses revealed no advantage (CAR expression 10% with the highest setting – 
2350V/15ms/2 pulses) and poor recovery. The addition of IL4 and IL7 in the first 24 hours following 
transfection does not improve the CAR expression. The isotype control antibody used to stain cells 
transfected at 2400V was consistently negative. 
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Figure 3-18 CAR expression increases progressively with higher voltages 24 hours following 
electroporation 
Data presented are average CAR expression +/- 1 SD. The Y-axis shows the average percentage of 
CAR expressing CD3+ lymphocytes the day following transfection. Each electroporation condition is 
listed as the voltage given with a single electroporation pulse of 20ms. Each condition had at least 3 
replicates with different donor PBMCs except for 2400V with IL4 & IL7 which had 2 only. All conditions 
represent cells rested in TCM overnight without added cytokines, except for the ‘2400V with IL4 & IL7’ 
which had these cytokines added overnight prior to harvesting. CAR, Chimeric Antigen Receptor; IL4, 
interleukin 4; IL7, interleukin 7; TCM, T cell media. 
 
 
3.4 Other findings 
A range of exploratory experiments with small sample sizes were performed to look into different 
transfection variables. 
3.4.1 Plasmid concentration for optimal transfection 
We wanted to test whether pCMV-PB was necessary for CAR integration and whether the previously 
identified optimal concentration of 5µg/ml of each plasmid remained valid, as found by Nakazawa et al 
(Nakazawa et al. 2009). PBMCs in Buffer T at 2x107/ml were electroporated at 2400V/20ms/1 pulse. 
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The findings suggest the optimal concentrations of transposase and transposon plasmids may be 
5µg/ml each. The range in recovery was 8-26% for PBMCs, and the CAR expression was highest with 
5µg of each plasmid (Figure 3-19).  
 
 
 
Figure 3-19 CAR expression with different vector ratios 
CAR, PB-CAR vector; PB, piggyBac transposase vector. n=1 replicates for PB 2.5ug and 7.5ug, the 
remaining conditions had 2 replicates. 
 
3.4.2 Increasing the PBMC concentration in electroporation buffer fluid 
The consumables for electroporation are expensive and non-reusable. This particularly applies to the 
electroporator pipette tips and the electroporation buffer solution (Buffer T), which are proprietary and 
only available from Invitrogen. We performed a set of transfections with a single donor which 
demonstrate that using a higher concentration of cells in solution for electroporation is feasible and 
appears to give equivalent results, whilst effectively halving the consumables required (see Figure 3-
20). 
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Figure 3-20 CAR expression and cell recovery in relation to different PBMC concentrations 
Increasing the concentrations from the recommended 1-2x107/ml appears to have no impact on 
recovery or CAR expression. 1 replicate for each condition. CAR, chimeric antigen receptor.  
 
3.4.3 Using superPBase transposase instead of standard pCMV-piggyBac 
The original piggyBac transposable element, including the transposase enzyme and the inverted repeat 
(IR) DNA segments flanking the transposable element, was recognised and isolated from the cabbage 
looper moth Trichoplusia ni in the late 1980s (Cary et al. 1989). By separating the transposase from the 
IRs the piggyBac transposase/transposon system provides a robust platform for transgene integration 
in cell therapies with some advantages over the other available transposase systems. These 
advantages include high and persistent activity in mammalian cell lines, higher payloads than other 
systems, and ‘footprint-free’ excision for reversible transgenesis if needed (Li et al. 2013). Recent 
‘molecular evolution’ techniques have markedly improved the transfection efficiency of the other main 
transposase system available, called the Sleeping Beauty system. Using these techniques to develop a 
more active Sleeping Beauty transposase vector, called ‘SB100X’, the gene transposition efficiency 
was improved 100-fold (Mates et al. 2009). Other groups have subsequently used this approach in 
piggyBac and have developed a hyperactive mutant transposase with 7 mutations (‘hyperactive 7pB’) 
which appears to increase gene delivery by up to three-fold over native piggyBac and SB100X, and 
also causes significant improvement in long term gene expression following transfection (Yusa et al. 
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2009, Doherty et al. 2012). In addition this enhanced hyperactive piggyBac transposase appears to be 
able to work on much larger transgene payloads without degradation in transfection efficiency, as 
opposed to SB100X where there is a progressive deterioration with increased insert sizes.  
 Given the theoretical advantages in terms of payload, long term transgene stability, and the 
commercial availability of the hyperactive 7pB superPBase (SBI, Mountain View, CA), we tested the 
standard piggyBac vector against the new superPBase in a single donor. PBMCs at a concentration of 
2x107/ml in Buffer T were transfected with PB-CAR using either standard pCMV-PB or superPBase, all 
at 5µg/ml, at electroporation settings 2400V/20ms/1 pulse. The results are summarised in Figure 3-21. 
SuperPBase decreased recovery by ~15% but increased CD3+ CAR expression from ~10% to almost 
40%. 
 
 
Figure 3-21 Transfection efficiency using superPBase is higher compared to standard pCMV-
Pbase 
1 replicate for each condition. piggyBac, standard pCMV-PB vector; CAR, chimeric antigen receptor. 
 
3.4.4 CAR expression using superPBase and an additional PB-transposon 
vector 
Theoretically two transgenes may be transfected into a cell of interest using the piggyBac system by 
transfecting the cell culture with a PB-transposase and two expression vectors, each containing the 
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transgene of interest. We performed a pilot study to verify that CAR expression was maintained using 
superPBase when an additional GFP transposon vector was added. PBMCs were prepared in Buffer T 
to a concentration of 2x107/ml. superPBase, PB-CAR and PB-EF1-GFP were added at a concentration 
of 5µg/ml each, and the mix was transfected by electroporation using the Neon® settings 
2400V/20ms/1pulse. Two control conditions included using superPBase and PB-EF1-GFP alone, and a 
positive GFP control using superPBase with the piggyBac GFP expression vector pIRII-eGFP. Results 
are shown in Figure 3-22. When both PB-EF1-GFP and PB-CAR plasmids were transfected with 
superPBase, CAR expression was maintained at ~40%, and recovery was 26%, despite the addition of 
an additional piggyBac transposon vector. GFP expression was seen in 9.5% of CD3 cells in the co-
transfected condition, compared to only 5.1% when this vector was tested without the presence of PB-
CAR. GFP expression was superior using pIRII-GFP compared to PB-EF1-GFP. 
 
 
Figure 3-22 Dual CAR and GFP expression using superPBase 
Recovery is expressed as the percentage of viable cells recovered compared to the original number 
transfected. CAR and GFP expression are expressed as the percentage expression within viable CD3+ 
cells. 1 replicate for each condition. CAR, chimeric antigen receptor; GFP, green fluorescent protein.
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Chapter 4 – Expansion of chimeric antigen receptor 
transfected peripheral blood mononuclear cells 
Once an optimised protocol for PBMC transfection had been established the next step was to increase 
CAR expression and transfected cell numbers in ex vivo tissue culture conditions. Previous work 
suggested that providing a signal through the introduced CAR by co-culture with cells expressing the 
cognate antigen, in this case CD19, could enrich CAR T-cell numbers in culture. This is demonstrated 
with the use of artificial antigen presenting cells engineered to express CD19 by Manuri et al (Manuri et 
al. 2010). Furthermore, the addition of cytokines particularly IL2, IL7 and/or IL15 to the electroporated 
cell cultures in order to enhance homeostatic or antigen-specific cell proliferation is routine in other 
publications (Singh et al. 2008, Nakazawa et al. 2009, Manuri et al. 2010). We hypothesised that 
adding IL2, IL7 or IL15 (alone or in combination) to the electroporated cell culture may enhance the 
expansion of CAR expressing T-cells.  
Thus in order to specifically enrich and expand the CAR T-cells, a CD19+ stimulator cell was 
needed. We initially chose to use NALM-6 for this purpose. NALM-6 is a CD19 expressing pre-B ALL 
cell line developed from a 19 year old male with relapsed ALL (Hurwitz et al. 1979). The variables for 
optimisation we tested included the optimal ratio of Responders (CAR-transfected PBMCs) to 
Stimulators (NALM-6 cells) (the R:S ratio) and the optimal mix of cytokines during the first culture period 
following transfection. 
4.1 Methods 
4.1.1 Transfection of PBMCs 
PBMCs from healthy donors were transfected according to the optimised parameters outlined in 
Section 3.3. PBMCs were thawed or harvested fresh, incubated overnight in TCM in a 12 well plate 
without cytokines added. For transfection, PBMCs were harvested and suspended to 4x107/ml in Buffer 
T. Purified superPBase and pCMV-CAR.CD19-28ζ were added at a concentration of 5µg/ml each. 
Electroporation with the Neon® system was performed using the electroporation settings 2400V/20ms 
pulse width/1 pulse. Transfected cells were then incubated overnight in a 24 well plate with TCM with 
no added cytokines at a concentration of 2x106/ml, 2mls in each well.  
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4.1.2 Expansion using NALM-6 stimulator cells 
On day 1 following transfection the PBMCs were harvested and resuspended in TCM at 1x106/ml, 1ml 
was added to each well of a 24 well plate. Separately cultured NALM-6 cells were harvested and 
irradiated to 45Gy. Irradiated NALM-6 were washed and resuspended in TCM at a range of 
concentrations varying from 10x106/ml to 0.1x106/ml. 1ml was added to each well of transfected 
PBMCs resulting in R:S ratios from 1:10 to 10:1.  
 Once an optimal R:S ratio was identified, variations of cytokine types were studied in order to 
optimise CAR T-cell expansion. The cytokines assessed included IL-2 at a concentration of 50U/ml for 
antigen specific cell expansion, and the homeostatic expansion cytokines IL-7 and IL-15, both at a 
concentration of 10ng/ml. Culture medium was replenished with TCM and appropriate cytokines every 
2-3 days of incubation.  
 CAR T-cell expansion was assessed in terms of recovery by trypan blue exclusion and CAR-
expression in viable CD3+ cells by FACS at day 8. The optimised conditions were then reassessed for 
expansion from day 8 to day 15 with different R:S ratios and cytokine mixtures. Recovery results are 
expressed as ‘fold expansion’, i.e. normalised to 1 on the day of harvest and stimulation, 24 hours 
following transfection by electroporation. 
4.2 Recovery and expression with different Responder to 
Stimulator ratios 
4.2.1 Cell recovery 8 days following incubation in different R:S ratios 
Summary results for total viable cell recovery at day 8 by different R:S ratios are shown in Figure 4-23. 
Recovery is expressed as the viable cell count determined at day 8 divided by the original viable cell 
number plated for expansion from day 1, calculated as ‘fold expansion’. There is a suggestion of a 
trend for increased cell recovery with higher concentrations of stimulators, i.e. with lower R:S ratios (test 
for linear trend: P-value 0.0011; one way ANOVA). The two control conditions gave different results, 
with the average recovery for the No Template Control after one week being higher than the non-
transfected PBMCs, which were cultured from the Buffer T mixed with vectors but not electroporated 
(P-value 0.0181, two-tailed paired t test). The lowest recovery was seen in transfected PBMCs 
incubated without the addition of NALM-6 stimulators, with average expansion of 0.36+/-0.23 only. The 
expansion using a 4:1 R:S ratio was 1.20 +/- 0.92. 
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Figure 4-23 Viable cell recovery appears highest with a high ratio of NALM-6 stimulators to CAR 
transfected PBMCs 8 days following transfection 
Irradiated NALM-6 cells were added as stimulators from day 1. Data are expressed as the average fold 
expansion compared to day 1 after transfection +/- 1 standard deviation. All conditions had at least 3 
replicates (range 3 to 7) except for ‘Nil stimulators’ which had 2. R:S ratio, responder to stimulator ratio; 
NTC, no template control; PBMC, peripheral blood mononuclear cell. 
 
4.2.2 Chimeric antigen receptor expression following incubation in different 
R:S ratios 
Summary results for CAR expression in viable CD3+ cells 8 days following transfection in different R:S 
conditions are summarised in Figure 4-24. The highest CAR expression was seen with an R:S ratio of 
4:1, both in terms of average expression within viable CD3+ cells (52%+/-9%), and also when 
expressed as a percentage of total FACS events (6%+/-2%). The CAR expression increased for the 4:1 
R:S ratio condition with respect to cells incubated without NALM-6 stimulators: average 52% vs 28% 
respectively (95% confidence interval for difference 3.765% to 45.47%, P=0.0221, one way ANOVA). 
Both control conditions returned CAR expressions of <0.5%. 
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Figure 4-24 CAR expression appears highest with a ratio of 4:1 CAR transfected PBMC to each 
NALM-6 stimulator 8 days following transfection 
Irradiated NALM-6 cells were added from day 1 in different R:S ratios. Columns represent average CAR 
expression + 1 SD expressed both as a proportion of viable CD3+ cells (%CD3) and as a percentage of 
total FACS events (%total). All conditions had at least 3 replicates (range 3 to 7) except for ‘Nil 
stimulators’ which had 2. CAR, chimeric antigen receptor; R:S, responder to stimulator; NTC, no 
template control. 
 
4.3 Recovery and chimeric antigen receptor expression with 
different cytokine mixtures 
The optimal R:S ratio for expansion of CAR expressing T cells at day 8 was judged to be 4:1, with 
irradiated NALM-6 as stimulators, based on optimising CAR expression in conjunction with modest 
PBMC expansion. The following experiments were done using irradiated NALM-6 in a 4:1 ratio except 
where specified. 
4.3.1 Cell expansion 8 days after transfection following incubation with 
different cytokines 
Results for PBMC expansion on day 8 after transfection using different combinations of IL2, IL7 and 
IL15 are summarised in Figure 4-25. Data are expressed as fold expansion determined at day 8 by 
counting the viable cells by trypan blue exclusion and dividing that number by the original cell number 
plated for expansion from day 1. There was no apparent difference in expansion results using IL2, IL7, 
or IL15 alone or in combination after 8 days of incubation. Recovery results for transfected PBMCs 
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incubated without stimulator cells were universally poor, with the best recovery seen with addition of all 
three cytokines averaging 0.43 only.   
 
 
Figure 4-25 No difference in fold-expansion with different combinations of IL2, IL7 or IL15 added 
to culture media 
Data are expressed as average fold expansion compared to day 1 after transfection +/- 1 standard 
deviation. Irradiated NALM-6 cells were added in an R:S ratio of 4:1 from day 1 along with cytokine; 
Replicates ranged from n=1 (‘Nil cytokines, IL2’) to n=5 for each condition. R:S, responder to stimulator 
ratio; IL, interleukin.  
 
4.3.2 Chimeric antigen receptor expression 8 days after transfection following 
incubation with different cytokines 
Results for CAR-expression by CD3+ cells and as a percentage of total events with different cytokine 
mixtures are summarised in Figure 4-26. The range in CAR expression within viable CD3+ cells was 
29% to 67%, there was no detectable differences between conditions (p=0.4525, one way ANOVA). 
The average CAR expression for PBMCs incubated with NALM-6 without cytokines was 52% +/- 9%. 
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Figure 4-26 No difference in CAR expression 8 days following transfection with different 
cytokines 
CAR expression is expressed as an average percentage of viable CD3+ cells or of total events +1 
standard deviation. Replicates ranged from n=1 (‘Nil cytokines, IL2’) to n=5 for each condition. CAR, 
chimeric antigen receptor; R:S, responder to stimulator; IL, interleukin. 
 
 
4.4 Expansion of chimeric antigen receptor T-cells using 
autologous PBMCs as stimulator cells 
Having established that the optimal R:S ratio with irradiated NALM-6 cells was 4:1, and that the addition 
of cytokines for the first week after transfection appeared to make little difference to expansion or CAR 
expression, we performed a pilot set of expansion experiments using irradiated autologous PBMCs as 
the stimulator cells. The rationale for this was that autologous PBMCs should be cheaper and easier to 
implement in animal and human experiments when compared to a malignant cell line, that autologous 
PBMC fractions will include CD19-expressing B cells which could serve as a source of CD19 
stimulation for CAR transfected CTLs, and also that PBMCs will be much easier to source than other 
stimulator cells for future experiments. For these experiments, autologous PBMCs were irradiated to 
45Gy and co-cultured with the transfected PBMCs from day 1 in a 1:1 ratio at 1x106/ml, with the 
addition of IL2 (50U/ml), IL7 and IL15 (10 ng/ml each) in each well. 
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4.4.1 Expansion 8 days following transfection and co-culture with irradiated 
autologous PBMCs 
Expansion results for the first week expansion experiments comparing different stimulator cells are 
shown in Figure 4-27. Autologous PBMCs demonstrated a clear increase in cell numbers at day 8 
compared to day 1, with a mean fold expansion of 3.66 +/- 1.19. The difference between NALM-6 (with 
or without cytokines) and PBMCs was statistically significant: P<0.05 for both comparisons using one 
way ANOVA. 
 
 
Figure 4-27 Expansion of PBMC 8 days after transfection is highest when incubated with 
irradiated autologous PBMCs 
Data are expressed as the average fold expansion compared to day 1 after transfection +/- 1 standard 
deviation. N=4 replicates for each condition. R:S, responder to stimulator ratio; IL, interleukin; PBMC, 
peripheral blood mononuclear cell. 
 
 
R
:S
 4
:1
 w
ith
 N
A
LM
-6
, n
o 
cy
to
ki
ne
s
R
:S
 4
:1
 w
ith
 N
A
LM
-6
, I
L2
/7
/1
5
R
:S
 1
:1
 w
ith
 a
ut
ol
og
ou
s 
P
B
M
C
, I
L2
/7
/1
5
0
2
4
6
F
o
ld
 e
x
p
a
n
s
io
n
P=0.0048
P=0.0092
 
85 
 Chapter 4 - Results 
 
4.4.2 Chimeric antigen receptor expression 8 days following transfection and 
co-culture with irradiated autologous PBMCs 
Results for CAR-expression in CD3+ cells and as a percentage of total events 8 days after transfection 
and culture with irradiated autologous PBMC or NALM-6 cells are summarised in Figure 4-28. There 
was no difference in the three conditions (irradiated NALM-6 with or without the addition of cytokines, 
and autologous PBMCs) in terms of CAR expression as a percentage of CD3+ cells, with averages 
ranging from 58% to 81% (P-value 0.2248, one way ANOVA). However there was a surprising 
improvement in CAR expression when assessed as a proportion of total FACS events, with an average 
recovery of 28%+/-8%, compared to <5% with NALM-6 stimulators (overall P-value <0.0001 one way 
ANOVA) suggesting there were more viable CD3+ cells in the autologous PBMC stimulated cultures 
after 8 days of co-culture. As a comparator, CAR positivity from the day 1 transfected cells is shown as 
well, with average CAR expression in CD3 cells of 30% +/- 8%. 
 
 
 
  
Figure 4-28 Relative CAR expression 8 days after transfection is equivalent when cultured with 
irradiated NALM-6 or autologous PBMCs 
CAR expression is expressed as the average percentage of viable CD3+ cells or as a percentage of 
total events by FACS + 1 standard deviation. The ‘Baseline’ condition denotes CAR expression 1 day 
after transfection, prior to stimulation and co-culture. N=4 replicates for each condition. CAR, chimeric 
antigen receptor; R:S, responder to stimulator; IL, interleukin, PBMC, peripheral blood mononuclear 
cell. 
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4.5 Expansion of chimeric antigen receptor T-cells in the second 
week following transfection 
Drawing on established methods of CMV-specific CTL generation, we trialled a number of different 
conditions for expansion from day 8 to day 15 following transfection, with a second dose of stimulator 
cells added on day 8. In these experiments, transfected cells originally stimulated with irradiated 
autologous PBMCs were harvested and resuspended to 1x106/ml in TCM and replated in a 24-well 
tissue culture plate. Autologous PBMCs irradiated to 45Gy in a 1:1 ratio along with IL2, IL7 and IL15 in 
identical concentrations to week 1 were added. For cells originally stimulated by irradiated NALM-6 in a 
4:1 R:S ratio, the cultures were harvested and resuspended in TCM and cytokines at a concentration of 
1x106/ml before addition of irradiated NALM-6 in an R:S ratio of 4:1 or 10:1. We also tested 2nd week 
expansion with NALM-6 in a 4:1 ratio by seeding a gas permeable tissue culture flask system (G-REX, 
Wilson Wolf Manufacturing, New Brighton, MN) on day 8. G-REX flasks have been shown to improve 
suspension cell culture yields when compared to culture plates in a number of settings (Bajgain et al. 
2014). 
4.5.1 Expansion during the second week after transfection 
Expansion results on day 15 of culture relative to day 8 are summarised in Figure 4-29. Results are 
expressed as fold-expansion of viable cells as assessed by trypan blue count compared to the count at 
day 8. Overall there was no significant difference in expansion: P-value 0.1081 by one way ANOVA. 
The average fold expansion for autologous PBMCs was 10.24 +/- 2.92, and for NALM-6 in an R:S ratio 
of 4:1 9.96 +/- 6.01. The G-REX flask expanded significantly less than the equivalent 24-well plate, with 
a mean expansion of 2.34 +/- 1.72 only, mean difference of 6.653 (95% CI 0.6652 to 12.64, adjusted P-
value 0.0347; one way ANOVA).   
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Figure 4-29 Expansion of transfected PBMCs is equivalent when co-cultured with NALM-6 or 
autologous PBMC from day 8 to day 15 
Transfected cells were harvested and restimulated day 8 following transfection in the above culture 
conditions. Fold expansion refers to the viable cell count divided by the baseline count, in this case on 
day 15 relative to day 8. The ratio refers to the R:S ratio. Replicates were n=3 for the G-REX condition, 
and n=4 for the remainder. R:S, responder to stimulator; G-REX, gas permeable rapid expansion 
culture flask; PBMC, peripheral blood mononuclear cell count; ns, not significant. 
 
4.5.2 Chimeric antigen receptor expression during the second week after 
transfection 
CAR expression results for CD3+ cells and as a percentage of total events are shown in Figure 4-30.  
There was no difference in CAR expression between conditions either in terms of CD3+ CAR 
expression or when expressed as a percentage of total events by FACS (P-values 0.1665 and 0.3680 
respectively, one way ANOVA). The mean CD3+ CAR expression in the autologous PBMC stimulated 
cells was 64.75% +/- 10.64%, and in the 4:1 NALM-6 stimulated cells 78.2% +/- 8.36%. 
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Figure 4-30 Expression of CAR day 15 following transfection is high and equivalent across 
different culture conditions 
CAR expression is expressed as average percentage of viable CD3+ cells or as a percentage of total 
events by FACS + 1 standard deviation. Replicates were n=3 for the G-REX condition, and n=4 for the 
remainder. G-REX, gas permeable rapid expansion culture flask; PBMC, peripheral blood mononuclear 
cell count.  
 
 
4.6 Overall chimeric antigen receptor expansion 
In order to combine the expansion and CAR expression data, we calculated the overall expansion of 
the transfected PBMC cultures after two weeks of incubation in relation to day 1 with respect to overall 
expansion of PBMCs and specific expansion of CAR transfected T cells (CAR T-cells). To calculate the 
CAR T-cell specific expansion we divided the total number of CAR T-cells at day 15 (CAR% total X 
viable cell recovery day 15) for each condition divided by the original number recovered on day 1 
following transfection (CAR% total X viable cell recovery day 1). By day 15 there was a significant 
difference in the overall expansion for cells stimulated 4:1 with NALM-6 cells (mean fold-expansion 
11.51 +/- 7.95), compared to cultures stimulated with autologous PBMCs (mean fold-expansion 42.98 
+/- 17.49) (P-value 0.0386; two tailed paired t test). For expansion of CAR T-cells specifically there was 
a trend to significance only, which did not reach statistical significance: mean fold-expansions 117.7+/-
146.4 vs 457.0+/-275.4 for NALM-6 vs autologous PBMC cultures (P-value 0.0600; two tailed paired t 
test). The results are shown in Figure 4-31. Although there is considerable variation between CAR T-
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cell expansion between different donors, in all cases tested there was considerable CAR-T expansion 
compared to the baseline (day 1) result. There were no culture failures in these experiments, and the 
feasibility of creating a clinically useful CAR T-cell product appears high at least when starting with 
healthy donors, albeit dependent on the starting PBMC number prior to electroporation.   
 
 
 
 
 
Figure 4-31 Overall and CAR T-cell expansion from day 1 to day 15 is highest using irradiated 
autologous PBMC as costimulatory cells 
Panel A shows results for overall cell expansion from day 1 to day 15. Panel B shows results 
specifically for CAR T-cell expansion, which takes into account the absolute recovery of CAR T-cells on 
day 1 and day 15. Data are mean fold-expansions +/- 1 SD compared to day 1 post transfection. CAR-
T, chimeric antigen receptor expressing CD3+ cell; PBMC, peripheral blood mononuclear cell. 
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Chapter 5 –Transfection results in Cytomegalovirus 
specific T cell cultures 
The original aim of these experiments was to develop an optimised protocol for robust CAR.CD19 
expression by CMV-specific T cells for use in future cell therapy trials in humans. Virus-specific CAR 
redirected T cells would have significant benefits in the allogeneic HCT setting in terms of safety, as 
CTLs do not demonstrate a risk of GvHD as opposed to unselected DLI (Melenhorst et al. 2010), and 
also would provide an attractive platform for human CAR therapy trials, as many centres have 
established cell-culture virus-CTL programs running for use in their allogeneic recipients already.   
 A series of pilot experiments were performed to demonstrate CAR expression in CMV-CTLs 
following transfection with pIRII-CMV-CAR.CD19-28ζ. 
5.1 Methods 
Cytotoxic T lymphocytes were generated by one of two methods.  
5.1.1 Generation of Cytomegalovirus-specific T-cells using adherence 
monocyte stimulation 
PBMCs from an HLA-B*07 expressing, CMV-seropositive donor were harvested or thawed, suspended 
to 4x106/ml in TCM and incubated in a 12-well plate for 2 hours (1ml per well). After 2 hours the non-
adherent cell fraction was washed off,  resuspended to 2x106/ml in TCM and incubated in a 24-well 
plate, 1ml per well. The adherent fraction (predominantly monocytes) was incubated with 10µg/ml of 
TPR-peptide in TCM. After 2 hours the primed monocytes were harvested with a cell scraper from each 
well, washed in DPBS, resuspended to 1x105/ml in TCM, and irradiated to 30Gy. The primed, irradiated 
monocytes were then added to each well of the non-adherent PBMCs for a Responder to Stimulator 
ratio (R:S ratio) of 20:1. Cells were incubated for one week with TCM replenished every 2-3 days as 
necessary.  Cells were restimulated with TPR-peptide on day 8 using PBMCs from the same donor that 
were thawed and treated as above. The CTL culture was resuspended to 2x106/ml and co-cultured with 
the irradiated monocytes at an R:S ratio of 20:1. IL2 was added at a concentration of 20U/ml. Between 
day 8 and day 21 the culture medium was replenished with TCM and IL2 every 2-3 days. From day 14 
the IL2 dose was increased to 50U/ml, and the cells were harvested for transfection on day 21.  
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5.1.2 Generation of Cytomegalovirus-specific T-cells using direct stimulation 
by TPR peptide 
In an attempt to simplify the process for generation of TPR-peptide specific HLA-B*07 restricted CMV-
CTLs, we devised a method for generating CTLs by direct PBMC simulation with TPR-peptide. This 
method does not require adherence isolation of monocytes. PBMCs were selected from a donor known 
to be HLA-B*07 positive and CMV-seropositive. PBMCs were washed and suspended 2x106/ml in TCM 
then plated 2ml per well on a 12-well culture plate. To each well was added TPR-peptide to a 
concentration of 10µg/ml. The cells were incubated for one week, with TCM being replenished every 2-
3 days. Cells were restimulated on day 8 with autologous PBMCs incubated overnight in TCM with 
TPR-peptide 10µg/ml. These cells were irradiated and added to the T cell culture cells in a 1:1 ratio 
along with IL2 at 20U/ml. The resultant cultures are referred to as ‘TPR-stimulated CTLs’ in the text.  
5.1.3 Transfection of Cytomegalovirus-specific T-cell cultures 
CTLs were harvested for transfection after 2 to 3 weeks of culture. Transfection of CMV-CTLs was 
performed identically to the method used for PBMCs, except that IL2 was added to the transfected cells 
immediately after transfection, as the abrupt withdrawal of IL2 could affect CTL survival independently 
of the electroporation. 
5.1.4 Flow cytometry of Cytomegalovirus-specific T-cell cultures 
Flow cytometry proceeded identically to that for PBMCs with the addition of HLA-B*07-PE TPR tetramer 
(iTAg MHC Tetramer, Beckman Coulter, Fullerton, CA) to identify CMV specific cells. 
5.2 Generation of B7-TPR tetramer positive T-cells  
CMV-specificity of the CTL cultures were assessed using HLA*B:07-TPR tetramers by flow cytometry. 
The tetramer expression by day 15 in the TPR-stimulated CTL culture was ~30%, compared to 77% 
using monocyte stimulation. Figure 5-32 shows representative flow cytometry plots from day 15 of 
culture.   
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Figure 5-32 Tetramer expression in CTL cultures at day 15 of culture 
Plot A demonstrates HLA*B7 CMV tetramer expression in TPR-stimulated CTLs. Plot B demonstrated 
B7 tetramer expression in monocyte stimulated CTLs. CMV, cytomegalovirus; CTL, cytotoxic T 
lymphocyte; PBMC, peripheral blood mononuclear cell; TPR, TPR-peptide derived from CMV pp65 
antigen. 
 
5.3 Transfection of Cytomegalovirus specific T-cells with 
CAR.CD19-28ζ 
5.3.1 Recovery 
Results for recovery 24 hours following electroporation of CMV-CTLs are presented in Figure 5-33. 
Recovery is defined as per Section 3.3 above comparing the number of viable cells recovered 24 hours 
following electroporation as counted by trypan blue exclusion as a percentage of the cell number 
originally electroporated. The non-electroporated CTL control (containing vector but not electroporated) 
continued to expand in the TCM with IL2, with a mean recovery of ~150%. However the recoveries for 
all transfected samples were globally poor, with an average recovery of 14%. The recoveries tended to 
be poorer with higher electroporation voltages, with the average recovery at 2400V being 5%. 
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Figure 5-33 Recovery in CMV-CTL cultures 24 hours following electroporation is uniformly poor 
The ‘CTL control’ was derived from CTLs suspended in Buffer T mixed with vector but not 
electroporated. The ‘NTC’ condition was CTLs suspended in Buffer T without vector and electroporated 
at 2400V. Replicates ranged from n=2 to n=4 for each condition. CMV, cytomegalovirus; CTL, cytotoxic 
T lymphocyte; NTC, no template control. 
 
 
5.3.2 CAR and tetramer expression 
Results for CAR expression in CD3+ cells and tetramer expression in CTLs after transfection are 
presented in Figure 5-34. CAR expression was higher with increasing voltage parameters to a 
maximum of ~10% at 2300V. CAR expression was less than 5% in all settings lower than 2300V. 
Average tetramer expression in the CTL control was 42%. This value was mildly reduced after 
electroporation to an average of 33%. Dual expression of both CAR and Tetramer was also assessed 
but was generally low. For example at 2300V there was an average of 11% of CD3+ cells co-
expressing both CAR and tetramer.  
 
Expansion of transfected CMV-CTLs over 1 week was attempted in several donors without success as 
cell numbers decreased from day 1 and CAR expression was lost. In addition there was a decrease in 
Tetramer expression (data not shown). 
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Figure 5-34 Expression of HLA*B7-TPR tetramer and CAR 24 hours after transfection 
Data are presented as average percentage expression in CD3+cells + 1 SD where applicable. 
Replicates ranged from n=2 to n=4 for each condition. CAR, chimeric antigen receptor; CTL, cytotoxic T 
lymphocyte; NTC, no template control.  
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Chapter 6 
Summary of Results 
Based on the experiments above we found the optimal electroporation conditions for CAR expression in 
PBMCs to be the highest single pulse available, i.e. 2400V/20ms/1pulse. Pilot experiments suggested 
benefits to increasing the concentration of cells in Buffer T prior to electroporation to 4x107/ml, and 
using the optimised commercially available expression vector superPBase instead of standard 
piggyBac. Results from this chapter indicate that the best choice of stimulator cells is irradiated 
autologous PBMCs in a ratio of 1:1 added day 1 and day 8 after transfection, although further titration 
of PBMC ratios will be necessary. Following transfection, the data generated from these experiments 
suggests that the optimum conditions for culture are incubation in TCM with IL2, IL7 and IL15.  
 Robust transfection and expansion of CMV-specific CTLs was not demonstrable in our 
experiments, and needs to be approached in a different fashion.   
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Figure 6-35 Suggested method for PBMC transfection incorporating optimisation data 
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Discussion 
Through the work outlined in the results chapters above we have demonstrated a reliable and 
reproducible method for expression and expansion of a CD19-specific Chimeric Antigen Receptor 
transgene using piggyBac mediated integration into T-cells of healthy donors. This research will serve 
as a platform for future cell and gene therapy experiments for the Westmead Cell Therapies group. 
Using an iterative optimisation approach we were able to demonstrate several key findings with 
implications for the local CAR program which include: (i) the key importance of choosing the optimal 
electroporation voltage settings for initial transgene expression; (ii) choosing the optimal helper 
transposase plasmid and cell concentrations for electroporation also have substantial beneficial 
impacts on recovery and CAR expression; (iii) robust expansion of CAR modified T cells by co-culture 
with irradiated autologous PBMCs is highly feasible; and (iv) that analogous transfection of ex vivo 
cultured CMV-specific CTLs is unlikely to be successful using the same approach as PBMCs. Using 
piggyBac to transfect mammalian cell lines and primary human T cells with a CAR transgene has been 
done previously, but innovations of our approach include the use of the Neon transfection system 
instead of the Amaxa Nucleofector (Lonza, Basel, Switzerland), which has significant advantages in 
terms of flexibility of the electroporation programs, and we also demonstrate that using of autologous 
irradiated PBMCs to stimulate the cultures leads to selected outgrowth of CAR T-cells in useful 
numbers without the need for costly selection steps.  
 
Prior reports chimeric antigen receptor expression using transposase systems 
Ours is not the first group to attempt optimisation CAR.CD19 expression in T cells using non-viral 
transposase systems such as piggyBac, but our approach differs from other groups in several key 
ways. Singh and colleagues from the M.D. Anderson Cancer Centre (Houston, TX) have published on 
redirecting specificity of primary human T cells with second generation CAR by means of the Sleeping 
Beauty Transposase/Transposon system (Singh et al. 2008). The authors describe the development of 
the second generation ‘Codon Optimised’ CD19RCD28 CAR derived from their original second 
generation construct described by Kowolik et al (Kowolik et al. 2006). Using the Amaxa Nucleofector 
electroporation device (Lonza, Basel, Switzerland) they achieved CAR expression of 27% after 24 
hours. Thereafter they were able to increase CAR expression up to 38.9% over 28 days by means of 
stimulating with irradiated artificial Antigen Presenting Cells (aAPCs) every 7 days. The aAPCs are 
K562 cells, a non-adherent, MHC negative, Philadelphia-chromosome positive erythroleukaemia cell 
line, which have been genetically modified to express truncated CD19, 4-1BBL, MICA and membrane 
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bound IL15 for CAR T-cell stimulation. The paper goes on to demonstrate CAR T-cell phenotype and 
function ex vivo, the lack of persistent or integrated Sleeping Beauty transposase, and normal T-cell 
karyotype. 
 Students of Professor Mathew Wilson and Dr Cliona Rooney at the Center for Cell and Gene 
Therapy (Baylor College of Medicine, Houston, TX), have performed extensive work optimising 
piggyBac usage in primary human cells. Nakazawa and colleagues have published on the optimisation 
of piggyBac ‘transduction’ of a variety of different reporter transgenes, not including CAR, in primary 
human T cells from healthy volunteer donors (Nakazawa et al. 2009). Their piggyBac transposon 
plasmids all encoded for a CMV promoter, followed by either EGFP (enhanced GFP gene), ΔCD19 (a 
truncated CD19 epitope for cell selection purposes), or the suicide gene ‘iCasp9’. Key differences in 
their methodology include the use of CD3/CD28 Monoclonal antibody (CD3/CD28 mAbs) coated culture 
plates for selective outgrowth of T cells immediately following electroporation, the addition of IL2 
immediately following transfection, and the use of the Miltenyi Nucleofector Device instead of the Neon 
transfection system. Similar to our findings in cultured CMV-specific cells, they found gene expression 
and cell viability were poor when cells were transfected after stimulation with CD3/CD28 mAbs and 
abandoned that method. They focussed initially on the optimal ratio of transposase to transposon and 
found that 5ug of each plasmid was optimal for a day 1 transfection efficiency of 47.6%+/- 7.4%, and a 
viability of ~40%. These transfection efficiencies for eGFP are higher than our findings on day 1 (~30-
40%), however we did not optimise for GFP expression with our pIRII-eGFP plasmid, only for 
CAR.CD19. Interestingly they found a loss of GFP expression over time, ~50% over the first week of 
culture, and they attributed this to a difference in transfected cells versus transduced cells, where loss 
of expression occurs in cells without stable gene integration due to dilution with cell division. Next they 
assessed the role of additional cytokines (IL4, IL7, and IL15) finding that these cytokines appeared to 
increase the number of transduced T cells over time, and that IL15 alone was superior to the others 
alone or in combination. They also state their preference for IL15 alone relates to the known down 
regulation of the IL7 receptor with T cell activation, which is not an issue with IL15 receptor. They then 
went further to select transduced T cells which had been co-transfected with eGFP and ΔCD19 by 
means of magnetic beads conjugated to αCD19 antibodies on day 8. Using this method by day 22 they 
report over 80% of cells expressing both eGFP and ΔCD19. They then demonstrated markedly 
enhanced transgene expression and expansion by plating cells selected on day 8 with either irradiated 
autologous PBMCs or K562-aAPCs engineered to express CD80, CD86, and 4-1BBL for T cell 
stimulation. They found a mean expansion of 155 fold using irradiated autologous PBMCs and 296 fold 
for K562-aAPCs, with similar transgene expressions. By day 64 of culture over 80% of T cells were 
expressing both transgenes. Laurence Cooper’s group at M.D. Anderson Cancer Center later published 
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on CAR.CD19 expression optimisation using piggyBac based on the findings of the Nakazawa and 
Singh papers above (Manuri et al. 2010). In this case the transgene was the ‘codon optimised’ second 
generation CAR CoOpCD19RCD28, cloned into a piggyBac transposon plasmid (original description in 
(Kowolik et al. 2006, Singh et al. 2008)). Their method is summarised in Figure 6-36. The main 
difference with respect to the Nakazawa paper was the lack of a selection step. In brief the primary 
human PBMCs were electroporated with the Amaxa Nucleofector and piggyBac DNA plasmids, then 
stimulated from day 1 with 100Gy irradiated K562-aAPCs, which were gene modified to co-express 
CD19, membrane bound IL15 and GFP. Electroporated PBMCs were then cultured in the presence of 
IL2, and aAPCs were added every 7 days. Using this method they demonstrated outgrowth of CAR T-
cells, with ~50% expression of CAR in T cells after 3 weeks. They further demonstrated continued T 
cell expansion thereafter, such that by day 49 of culture 97% of T cells expressed CAR. They went on 
to demonstrate function and phenotype of transfected cells, and performed Fluorescent In-Situ 
Hybridisation (FISH) analyses with a CAR.CD19RCD28 probe showing only one copy of CAR per cell 
in 40-50 metaphases analysed. 
 
 
 
Figure 6-36 Schematic for CAR transfection and expansion method from Manuri et al 
PBMCs are electroporated for transfection, then expanded on artificial antigen presenting cells, which 
have been engineered to express CD19 and costimulatory molecules. Source: (Manuri et al. 2010). 
aAPC, artificial Antigen Presenting Cell; CAR, chimeric antigen receptor; EGFP, enhanced green 
fluorescent protein; PBMC, peripheral blood mononuclear cell. 
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Electroporation results 
Our analysis of CAR expression 24 hours following electroporation shows a clear ‘dose-response’ effect 
with increasing electroporation voltages, with the top single pulse electroporation parameter delivering 
the highest CAR expression, without significantly impacting on cell viability over lower voltages when 
plasmid DNA (pDNA) is present (see Figure 3-17 and Figure 3-18). The use of ‘electrotransfer’ for non-
viral transfer of charged macromolecules such as DNA was first demonstrated in the early 1980s 
(Neumann et al. 1982), and is proposed to work by the introduction of temporary pores in the lipid 
bilayer of cell membranes, hence the term electroporation, resulting in cross membrane transport of the 
molecule of interest. The simplest explanation for our finding of improved CAR expression at the 
highest voltage is that these settings lead to the highest transfer of pDNA into the T-cell nucleus. These 
findings contradict the companies’ recommendation not to exceed 2250V for primary PBMCs, 
emphasising the need for individual optimisation of protocols with differing gene modification systems 
targeting specific cell subtypes with varying transgenes. 
 The highest CAR.CD19 expression we demonstrated in the electroporation optimisation 
experiments was 26% using our standard PBase helper plasmid, which is lower than GFP expression 
using piggyBac published by Nakazawa and colleagues (Nakazawa et al. 2009), and roughly equivalent 
to that of Singh and colleagues for CAR.CD19 expression, who used the Sleeping Beauty system 
(Singh et al. 2008). When we switched to the use of superPBase transposase helper plasmid for later 
experiments our day 1 transfection results were substantially better, approximately 40% for CAR 
expression and 50% for GFP when using the pIRII-GFP plasmid (Figure 3-21 and Figure 3-22). This 
implies that factors to do with the plasmid design are likely to be as important for short term transgene 
expression, once the electroporation parameters have been optimised. As our two piggyBac 
transposase plasmids had different promoter elements (CMV IE for pCMV-PBase and POLr2A for 
superPBase) we cannot rule out an effect from these or other plasmid elements leading to the different 
transposon expression outcomes. In order to demonstrate that it was the superPBase transposase 
activity per se leading to the improved CAR expression we would need to redesign the helper plasmids 
to have the same promoter, however work done elsewhere does show convincing improvement in 
transposase efficiency using hyperactive piggyBac transposase over native piggyBac, despite similar 
protein expression levels (Yusa et al. 2011, Doherty et al. 2012).   
 In both the Nakazawa and Singh papers the Amaxa system was used for electroporation, and 
different pre-treatment and culture conditions were used for their PBMCs, but overall our CAR 
expression results compare favourably even without the use pre-transfection cytokines or CD3/CD28 
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activation steps in the cultures. From our results it is also apparent that electroporation per se did not 
lead to excessive cell death, as the recovery of viable cells 24 hours following electroporation was no 
different in the No Template Control condition, which were electroporated at 2400V/20ms, compared to 
the non-electroporated PBMC controls (Figure 3-17). There was a definite drop in cell viability when 
PBMCs were electroporated in the presence of plasmid DNA at any voltage, and yet there was no 
decrease in viability in cells electroporated with pDNA at lower voltages compared to higher voltages. A 
type 2 statistical error is possible in this case, but if such an effect is present it is likely to be small and 
outweighed by the very clear increases in CAR expression at the higher voltages. Our results support 
the notion that it is the presence of any plasmid DNA with electroporation that affects cell viability, not 
the electroporation settings per se. An interesting corollary is that the toxic effects of the pDNA do not 
appear to be dependent on transgene expression nor, presumably, gene integration. Perhaps the 
presence of any piggyBac transposase activity is enough to explain the cellular toxicity, or alternatively 
the toxic effects of the pDNA could be exerted at the level of the cytoplasm or exterior cell membrane in 
the presence of electroporation. Some putative mechanisms for this could include that RNA 
transcription and translation of piggyBac transposase enzyme in the cytoplasm could lead to cell 
damage and apoptosis, or that naked pDNA is innately toxic to the cytoplasm of eukaryotic primary 
cells. Alternatively it could be that the dilution of electroporation buffer with the vector solution (either 
water or Buffer TE usually) leads to excess cell death independent of the pDNA content. We were 
always cautious not to add more vector than 10% of the Buffer T volume as per the Neon system 
instructions, however it could be that the system is very sensitive to even small dilution changes. To 
determine which is the correct hypothesis, repeat optimisation experiments with pDNA in different 
concentrations could be used to ascertain the relative contribution to cell death from the pDNA content 
versus the volume of pDNA vector added to each electroporation.     
 Where the Neon transfection system and its predecessor, the Microporator (MP-100), differ 
from previous electroporation techniques is in the use of a pipette tip for the electroporation chamber 
instead of the traditional cuvette. Using this wire-type electrode results in a much smaller surface area 
for electroporation than the cuvette based systems, a design which was originally proposed to improve 
comparative cell viability (Kim et al. 2008). Most of the published papers using the 
transposase/transposon approach thus far have used alternative cuvette based electroporation 
systems such as the Amaxa, and the preponderance of the evidence is therefore with those systems. 
For our purposes it was the ease of adjusting electroporation parameters which attracted us to this 
transfection system, rather than perceived benefits in cell viability. In fact, based on the results in 
published reports using the Amaxa system, our viability results were not substantially different.  High 
volume Good Manufacturing Practice (GMP) grade ‘flow-electroporation’ systems have been developed 
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already, such as the MaxCyte system (MaxCyte, Gaithersburg, MD), which have been optimised for 
mRNA based transfection, not permanent CAR integration with transposases (Li et al. 2013). The 
electroporation settings for mRNA are likely to require orders of magnitude less in terms of voltage and 
pulse duration, as mRNA only need be transferred to the T-cell cytoplasm for protein translation. Using 
the Neon system will serve our purposes for all current ‘wet lab’ based experimental work, but in order 
to move towards early phase human clinical trials a change in transfection platform will be necessary, 
unless an analogous GMP grade electroporator to the Neon transfection system is developed. Even 
then further validation steps using the GMP components and reagents would be necessary.  
Expansion of chimeric antigen receptor T-cells 
Our optimised protocol defined the optimal cell population to act as feeder cells to be autologous 
irradiated PBMCs. Using this approach we found 457-fold expansion of CAR T-cell populations over 
two weeks in culture, which compares favourably to the results found in the Singh and Manuri papers 
mentioned above (Singh et al. 2008, Manuri et al. 2010). The provision of irradiated autologous PBMCs 
to the cultures probably aids CAR T-cells in several ways, including the presence of CD19 positive cells 
for CAR.CD19 stimulation in the B-cell fraction, as well as paracrine support from APCs within the 
monocyte and T-cell fraction. We originally utilised a CD19 positive leukaemia cell line (NALM-6) to test 
for expansion parameters, and the subsequent choice to use autologous PBMCs as well was based 
primarily on the concerns that cell line contamination in our CAR-T product would provide a serious 
hurdle to GMP certification and TGA approval for clinical trial usage, as well as several previous reports 
demonstrating that PBMCs could act as an effective feeder cell population. It is apparent from our 
results that the advantage in using irradiated autologous PBMCs over NALM-6 in terms of CAR-T 
expansion is most striking in the first week in culture: both cell types increased the CAR expression in 
T-cells from ~30% to ~70%, but the autologous PBMC cultures in addition increased the total T-cell 
population in each culture, and in addition the total cell numbers increased ~4-fold compared to <2-fold 
for the optimised NALM-6 condition, so that in absolute terms there were many more CAR T-cells 
present after one week (c.f. Figure 4-27 and Figure 4-28). Despite there being no difference in 
expansion of the NALM-6 and PBMC stimulated cultures during the second week (c.f. Figure 4-30), 
final CAR-T expansion was better overall using autologous PBMCs (c.f. Figure 4-31). The ratio of 
responder to feeder cells we used in our autologous PBMC conditions was 1:1 only, and given that 
there were substantial differences in total cell numbers and also CAR expression using different ratios 
of NALM6 cells, further steps to investigate the optimal culture ratios will be necessary.  
 Without the provision of irradiated feeder cells the CAR T-cell numbers dropped in the first 
week, along with a fall in CAR expression from ~30% to ~25%. Clearly feeder or stimulator cells will be 
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necessary for provision of adequate CAR-T numbers for further experiments, but it is interesting that 
CAR-expression had not fallen to the same degree as GFP expression in the experiments reported by 
Nakazawa et al, who report a 50% decrease in the first week (Nakazawa et al. 2009). The authors 
postulated that this difference was due to the difference in ‘transfection’ versus ‘transduction’, with day 
8 expression being reflective of permanent transgene integration instead of transient expression due to 
non-integrated transposon plasmid. In our case it is probable that the transfected PBMCs themselves 
provided a source of CD19-antigen for stimulation due to the presence of B-cells, and it is also possible 
that in our experiments there may have been fewer generations of cell division to dilute non-integrated 
transgene, as opposed to the CD3/CD28 stimulation provided in the experiments by Nakazawa et al. In 
conditions where CD19+ stimulator cells were present the increased CAR expression over the first week 
is almost certainly reflective of permanent transgene integration, as any T-cell with non-integrated CAR 
would be initially stimulated to divide, then lose CAR expression progressively and quiesce (or 
apoptose) with each subsequent generation of progeny. To prove this metaphase FISH experiments 
with a CAR.CD19 specific probe could be used to localise the CAR to chromosomes.  
 Our cytokine experiments in the first week reveal no substantive difference between different 
combinations of IL2, IL7 or IL15. The choice of which cytokines to use, if any, is a movable feast at 
present, and is highly likely to be individualised for each type of cell therapy experiment. Certainly IL2 
has a role in antigen-specific stimulation (e.g. virus specific CTL trials) and is likely to have a role in 
CAR experiments like ours, but may have no role in the expansion or function of other transgene 
experiments which do not entail antigen specific expansion such as GFP or other reporter genes. IL15 
seems to be popular in other ex vivo cultured experiments due to its established benefits in homeostatic 
maintenance in ex-vivo cell cultures, and potentially benefits on transfer to the in vivo setting in terms of 
CTL persistence and function (Lu et al. 2002, Mueller et al. 2008). In principle, the fewer cytokines the 
better in terms of transitioning to clinical grade conditions for human trials, and the use of IL15 alone is 
attractive in this sense also. IL2 may indeed be unnecessary when autocrine and paracrine effects in 
using irradiated autologous PBMCs are taken into account. All our cytokine optimisation experiments 
were performed in NALM-6 feeder cell conditions, and will need to be repeated for PBMCs.   
 Other groups have used K562-aAPCs instead of autologous PBMCs as stimulator cells with 
encouraging results. Clearly the use of ‘professional’ APCs in this manner provides benefits in terms of 
CAR T-cell nursing and provides the additional flexibility of delivery of any antigen of interest for use in 
future CAR experiments. Apart from the complexity of gene modifying K562s for each separate 
transgene experiment, the main foreseeable stumbling block would be the regulatory difficulties in 
involving gene modified cell lines in any part of the process in the delivery of a CAR-T product for 
human trials. For our purposes, with the CD19-specific CAR, irradiated autologous PBMCs will serve 
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well, but if a change in direction to other CAR targets is mooted then investment in K562-aAPCs or 
similar devices may be necessary in order to deliver adequate numbers of redirected T-cells.  
    
Chimeric antigen receptor transfection of Cytomegalovirus-specific cell 
cultures 
Using our approach for CAR-transfection we found that the cell viability and CAR expression results in 
CMV-specific T cell cultures were globally poor, with recovery averaging 14% and CAR expression 
~11% at best. The most likely explanation for this finding is that the innate sensitivity of CMV-CTLs to 
electroporation and pDNA mediated damage is higher compared to rested PBMCs. Supporting this 
contention is the observation that, in contrast to the PBMC optimisation experiment, for CMV-CTLs the 
‘no template’ conditions (electroporated without pDNA) returned lower cell recovery than the non-
electroporated controls (see Figure 5-33). All CMV-CTL experiments were performed in CTL cultures 
generated in ex vivo culture conditions by exposure of PBMCs to CMV-specific antigenic epitopes in 
the presence of IL2. Each case therefore included cells which had already been cultured for 3 weeks 
minimum, and were likely to have a degree of added physiological stress which rested PBMCs did not 
experience. CAR expression was demonstrable in small amounts, 10% being the best average 
expression at 2300V, as was dual CAR and CMV-tetramer expression in roughly equivalent proportions 
(i.e. 11% of tetramer positive cells co-expressed CAR.CD19). Despite that, the underlying rationale of 
CAR transfecting viral-CTLs is sound, the difficulty with generating CMV-CTLs in adequate numbers for 
transfection, the poor viability, and the limited CAR expression argue against pursuing the current 
method in future. Several alternative approaches could be attempted instead. The most rational 
approach to trial initially should be to transfect PBMCs from CMV-seropositive donors first, then use the 
transfected PBMCs to develop CMV-CTLs in a method identical to our current viral-CTL approach. 
Using this rationale one could expect ~30% of CMV-specific CTL precursors to become CAR positive 
initially as a stochastic event. The main foreseeable issue with this approach would be the subsequent 
provision of stimulator cells for either CAR- or CMV-specific CTL outgrowth in culture. This would be 
likely to provide mutually exclusive antigen stimulation and hence separate cell populations in the final 
product. To  get around this problem the two best choices would be to either use selection or sorting 
techniques for the CAR first in order to provide a highly enriched CAR-positive T-cell population to 
begin with, or to use aAPCs to provide both a CMV-specific and CAR-specific antigens on the same 
cell, or a combination of both approaches. The other broad approach for generating CAR-transfected 
CTLs would be to transfect and expand PBMCs for two or three weeks in the manner we have already 
demonstrated, then use those cell cultures to select CMV-specific CTLs with streptamer, 
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immunomagnetic beads, or IFN-gamma selection technologies. Such a selected population would be 
exclusively CMV-specific, and should harbour CAR-transfection rates similar to that of the parent 
population (~60% in our experiments after two weeks). The downside to both these approaches would 
be expense and extra steps involved with GMP certification in using genetically modified aAPCs or 
selection steps, and the small cell numbers one could expect from such selection procedures. 
Electroporation following immunomagnetic bead separation of, for example, virus specific or other cell 
population of interest is likely to be disappointing also, as the presence of residual magnetic beads in 
even small amounts will potentiate the electroporation induced cell toxicity, as we found in preliminary 
experiments of transfection in CD3+ selected cells from patients with B-CLL (data not shown). Negative 
immunomagnetic selection techniques, such as depleting all CD4+ cells to leave only CD8+ CTLs, is 
perhaps a more promising avenue, as immunomagnetic beads should not be linked to the cell 
population of interest in that case.  
 Although it was not the main objective of the CMV-CTL experiments, we did develop a shorter 
CMV-CTL generation technique than is currently in use by using monocytes or directly with the TPR-
peptide. The current technique in use by the Cell Therapies group at WMI depends on the generation of 
MoDCs (monocyte derived dendritic cells) for antigen presentation, which takes 8 days in culture prior 
to the addition of the PBMCs (Foster et al. 2003). By skipping this step and adding the HLA*B:07 
specific antigenic CMV peptide to either adherence isolated monocytes or directly to the PBMCs we 
generated cell cultures in one week less time than standard, which on immunophenotyping were 
predominantly CD3 positive cells with CMV-specific tetramer expression ranging from 30% to 80%. This 
approach has merit and could be adopted for use in other virus-specific cell therapy experiments, but is 
unlikely to replace the MoDC method in current clinical trial use, in particular for the benefits that 
functional MoDCs have in terms of processing whole viruses and other immunogenic molecules in an 
HLA-independent manner. 
Comments on the overall strategy for genetic modification of T cells to 
express chimeric antigen receptor  
Arguably the most successful demonstration of the potential for CAR-redirected T cells to date comes 
from the UPenn and NIH groups who have early phase clinical trials in patients with advanced CLL and 
ALL (Kalos et al. 2011, Porter et al. 2011, Porter et al. 2011, Grupp et al. 2013, Maude et al. 2014). 
Their programs involve lentiviral transduction of T-cells, which are derived from PBMCs which have 
been activated by CD3/CD28 mAbs, with a second generation CAR with a 4-1BB costimulatory domain 
instead of that from CD28 (Porter et al. 2006, Kalos et al. 2011, Porter et al. 2011). One important point 
to be gleaned from their initial case report is that they calculated only 5% of the T-cells were transduced 
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with CAR at the time of infusion, and the beneficial responses seen thereafter related to in vivo 
activation and expansion of the CAR-transfected T-cells. This does imply that successful CAR 
responses may not rely on the number of CAR T-cells transplanted to host, but rather on quality and 
persistence of CAR-T response in vivo and other factors. Indeed several other groups besides the NIH 
have moved away from non-viral transduction and towards using lentiviral transfection systems for the 
perceived benefits in terms of the production process, in particular with the high transfection efficiency 
of these systems. For example, due to the laborious CAR-T generation process employed with their 
naked plasmid DNA approach a group at the Fred Hutchison Cancer Research Centre (Seattle, 
Washington) have recently moved away from non-viral plasmid methods to a lentiviral approach for the 
generation of CD20 redirected CAR T-cells in their ongoing clinical trial (Till et al. 2012, Budde et al. 
2013). Lentiviral (LV) transfection systems are continuously being improved (now up to ‘4th generation’ 
systems), and recently have been shown to be able to be specifically targeted to cellular 
subpopulations of interest by the inclusion of scFvs in the envelope protein (Zhou et al. 2012). Taken 
together these observations throw some doubt on the need for non-viral transfection for CAR-T 
generation, and also question the need for generation of large numbers of CAR T-cells in the first place. 
After all, why culture cells to a transfection purity of >60%, as we have done, when the transfer of only 
5% transduced T-cells may be enough, as has been demonstrated in the Porter case report? (Porter et 
al. 2011) Nevertheless, it is not the case that only lentiviral systems are settled to have been the only 
way forward, and there remains a clear desirability to develop robust non-viral gene modification 
methods in our view. The main two benefits of transposase systems in comparison to LV systems 
remain (i) safety, with no chance of replication competent viral components combining with wild-type 
retrovirus, and a lower insertional mutagenesis risk based on studies of insertion sites; and (ii) 
scalability, with far more utilitarian economies of scale were clinical use of CAR T-cells to become 
widespread and routine.  
On the topic of the number of CAR T-cells needed, there is still a role to maximise the number 
CAR T-cells to be generated, if purely for experimentation purposes and for standardisation. The field 
as a whole will suffer unless safe doses can be defined, analogous to the minimum and maximum 
CD34+ cell doses required in allogeneic haematopoietic transplantation. In terms of the overall reliability 
of generating CAR T-cells for clinical use our approach has promise. With a mean expansion of CAR T-
cells ~450-fold over 2 weeks, one could generate 450x106 CAR T-cells for each starting 1x106 
transfected cells. Assuming a loss of 70% of PBMC after transfection (c.f. Figure 3-17) one could 
generate 1.9x106 CAR T-cells/kg of an average 70kg donor for a starting PBMC number of 1x106, a 
number which is easily achievable with a simple blood draw.  
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Finally, it is predictable that large numbers of CAR T-cells are likely to be required for cancer 
immunotherapy, and demand may outstrip any facilities’ ability to produce them in usable numbers in 
the current ‘personalised medicine’/cottage-industry style approach, unless we move towards a third-
party cell bank ‘off the shelf’ type model where large numbers of CAR-T would be highly desirable.   
Weaknesses 
Our research has several weaknesses. The optimisation of CAR expression in PBMCs and CMV-CTLs 
is a work-in-progress, in particular there is more work to be done in terms of defining the optimal ratios 
of feeder cells to transfected cells, and repeat the cytokine experiments using autologous PBMC feeder 
cells. The nature of the T-cell culture work is time-consuming and in many cases each experiment 
spanned more than a month. In conjunction with the limited availability of primary PBMCs for use in 
experiments, of necessity there were fewer replicates with each set of experiments than is optimal. This 
in turn led to wide confidence intervals and reduced power to detect significant differences in some 
cases. Unfortunately time constraints also meant that I was unable to further define the optimal PBMC 
ratio for stimulation and repeat the cytokine optimisation steps using PBMC stimulators. Despite this we 
were able to clearly demonstrate the improvement in CAR-expression with increasing electroporation 
voltages, and to find reliable and repeatable expansion of CAR T-cells when cultured with feeder cells. 
Transfection reagents using the Neon transfection system (and likely also any other commercially 
available electroporator system) are expensive and non-recyclable, in particular the electroporation 
buffer and electroporation pipette tips. Productivity was much improved once we were able to show that 
electroporation was feasible with higher cell concentrations than recommended, and that we could 
safely use each pipette tip in more replicates than the two recommended in the Neon instruction 
manuals. These two innovations led to an effective halving of our reagent use without impacting on 
quality. In these experiments we have not yet progressed on to immunophenotyping or function 
experiments in-depth with the CAR T-cells, as our main aims initially related to optimisation of 
transfection and expansion. Clearly these experiments will need to occur prior to incorporation of CAR 
T-cell into the clinical trial Cell Therapy program in our unit. We were unable to demonstrate CAR-
transfection of CMV-specific T cell cultures, which was one of our main initial aims. A fuller discussion 
of some potential alternative approaches has been undertaken above, but the fundamental aim of CAR-
transfecting virus-specific CTL cultures using piggyBac is sound, and would segue efficiently into the 
current virus-specific CTL trial program currently underway at Westmead hospital and elsewhere.  
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Potential future directions for the genetic redirection of T-cells 
For the use of genetically modified T-cells to become widespread the development path needs to follow 
that of a novel drug, with early phase trials focused on safety and efficacy, and later stage registration 
trials to be run in multiple centres with a comparator arm. To reach a phase 1 trial more preclinical work 
needs to be performed. The dominant safety concern is the potential to induce tumours derived from 
gene-modified T-cells through insertional mutagenesis, such as CAR transgene disrupting a tumour 
suppressor gene or driving a proto-oncogene. The most promising avenue to add a safety switch would 
be for the incorporation of a suicide gene such as iCasp9. Such a gene could be incorporated in to the 
piggyBac CAR transposon in cis via use of IRES or 2A sequences, and would therefore mandate that 
each CAR-redirected T cell also expresses a safety switch in case of adverse consequences. In terms 
of enhancements for efficacy, there are possibly benefits to be found by altering the design of the CAR 
signalling tail to other T-cell activating motifs such as 4-1BB, or in adding two together such as in the 
third generation CARs. The success of the NIH group in their non-specific approach to T cell 
modification is highly encouraging as well, but long term anti-tumour efficacy may well relate to the 
properties of the T-cell subset transduced as much as the CAR design per se. After all, when rested 
PBMCs or non-selected T-cell populations are transfected en masse then equal numbers of CAR-
modified T-regulatory cells are likely to be generated as well as anti-tumour redirected CTLs as well, 
and such CAR-redirected T-regs may lead to treatment failures if they were to expand in vivo like the 
CTLs.  
 From this author’s perspective the most promising approaches are likely to come from CAR-
modifying T-cell subsets with long lived ‘stemness’  properties, such as memory T cell populations 
recently identified by a group at the NIH (Gattinoni et al. 2011), or the Fred Hutchison Cancer Research 
group (Terakura et al. 2011). Many open questions remain about the optimal ancillary treatment to be 
given along with CAR T-cells in human trials, and murine and other animal experiments will be required 
before proceeding to phase I human trials. For example, should patients receiving CAR T-cells receive 
lymphodepleting chemotherapy first, as they do in the ongoing UPenn and NIH studies? Or is there a 
role for administration of IL2 after CAR-T administration in order to supply an additional proliferation 
signal to the cells? Finally, the CAR-T approach needs to be demonstrated to be successful in at least 
one target tumour antigen, and then to be tested against other targets. CD19 is a very attractive target 
as expression is limited to native B-cells and tumours, and there are already early successes in this 
space. There is a huge unmet clinical need for cell and gene therapy approaches to cancer therapy, 
and haematopoietic tumours are likely to provide the most abundant opportunities for CAR T-cells due 
to the integration of cell therapy as an established modality already, coupled with the immunological 
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nature of the tumour cells themselves. Should the CAR.CD19 approach be deemed a success, then 
focusing on myeloma therapy is an attractive option, particularly given the incurable nature of this 
disease, the plethora of potential antigenic targets on myeloma cells, and the lack of therapeutic 
options in multiply relapsed disease. 
Near term future research priorities 
Several promising avenues have been identified in the PBMC work presented in prior chapters, but 
more work remains to be done in order to define the optimal CAR expression and expansion 
parameters with respect to feeder cell concentrations and cytokines. An optimum CAR-T generation 
recipe will provide a platform to take towards an early phase clinical trial in patients suffering from CD19 
positive malignancies, once phenotype and function experiments have been completed. The goal of 
expressing CAR in virus-specific CTL cultures should not be abandoned, and several methods to trial 
have been outlined in the discussion above. A proposed list of research priorities is as follows: 
 Responder:Feeder ratio optimisation experiments to be repeated with irradiated autologous 
PBMCs 
 Repeat cytokine addition experiments with the irradiated autologous feeder cells 
 Extend culture experiments to 3 and 4 weeks to determine kinetics of continuous CAR-T 
expansion 
 Immunophenotype experiments to define percentage of T-cell subsets CAR modified and at 
which time points in culture 
 CAR T-cell function experiments with CD19+ and CD19- cell lines, in terms of cytokine flow 
cytometry, IFN-g elispot, and cell lysis assays 
 Redesign CAR transposon to include a suicide gene switch in cis and driven from the same 
promoter, and repeat validation transfection experiments with this new transposon 
 Karyotyping and FISH for insertion point and CAR copy number analysis of CAR T-cells 
 Reattempt CAR-expression in CMV-specific T cells via the methods outlined in the discussion 
text above 
 Develop a highly sensitive and quantitative RQ-PCR method for detecting and quantifying 
CAR-T numbers after infusion 
 Move towards early phase human trial using the CAR-T manufactured from PBMCs as above 
with clinical grade ingredients in allogeneic transplant recipients harbouring residual CD19+ 
disease 
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Conclusion 
We have demonstrated stable integration and expansion of a CD19-directed chimeric antigen receptor 
into primary T-cells derived from healthy donors by means of the piggyBac transposase/transposon 
system with electroporation, and these results will serve as the platform for future pre-clinical validation 
experiments and early phase clinical trials which will benefit patients with CD19+ tumours. The field of 
redirected T-cell therapies is only just beginning, and in order to meet the safety requirements of 
regulatory bodies and the production requirements of future clinical need, non-viral transfection 
methods such as the piggyBac system will have major advantages over lentiviral based transfection 
methods. With the use of a non-viral transfection method and irradiated autologous PBMCs for 
expansion instead of costly selection or artificial-APC steps, our method for CAR T-cell production is 
simpler and faces fewer regulatory hurdles than other published protocols for CAR-T production, and is 
a promising platform for CAR-redirection of T-cells towards other tumour antigens. An early phase 
clinical trial of CD19 redirected CAR T-cells based on these results is now planned.  
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